[
  {
    "sentence": "Among these DEGs, SLC31A1, a copper transporter, was highly expressed in the recurrent tumor specimens (Fig. 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Meanwhile, a gradually increasing SLC31A1 was detected in advanced-stage tumor specimens compared to those in the early stage (Fig. 1B and C).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "To further explore the prognostic value and expression of SLC31A1, the TCGA database was analyzed, and the result demonstrated that SLC31A1 expression was significantly upregulated in breast invasive carcinoma (BRCA) samples compared to the paired normal samples (Fig. 1D).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Additionally, higher SLC31A1 expression levels predicted poorer overall survival and progress-free interval survival rates than patients with lower SLC31A1 expression levels (Fig. 1E and F).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel E",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The results in Fig. 1G showed that SLC31A1 expression was significantly up-regulated in breast tumor tissues with ≥25-75% stained cells, while its corresponding normal tissues were moderately stained or unstained.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel G",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Data were presented as means ± SD. ⁎⁎P<0.01, ⁎⁎⁎P<0.001, ⁎⁎⁎⁎P<0.0001.SLC31A1 expression levels are up-regulated in ER-positive breast cancer patients\nIn this part, we verified higher expression of SLC31A1 in BRCA tissues compared to normal tissues through TIMER analysis (Fig. 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Despite detecting a positive correlation between SLC31A1 and ERBB2 (HER2) in BRCA samples, there was no significant difference observed between SLC31A1 and HER2 in BRCA-Basal and -Her2 specimens (Fig. 2B-E).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Additionally, no significant difference was detected between SLC31A1 expression and PGR expression in BRCA-Basal and BRCA samples (Fig. 2B and C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In vitro studies further demonstrated that SLCA31A mRNA and protein expression levels were higher in ER-positive breast cancer cell lines (T47D, MCF7, BT474, ZR-75-1), while being undetectable or slightly expressed in ER-negative breast cancer cell lines (MB231, HCC1954, MB453) and the normal epithelial cell line (MCF10A) (Fig. 2F-H).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "RT-qPCR results demonstrated that SLC31A1 was highly expressed in ER-positive breast cancer specimens in comparison to the matched adjacent normal tissues (Fig. 3A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Notably, much stronger SLC31A1 gene expression levels were detected in ER-positive breast cancer samples from patients with recurrence (R) than those of the patients without recurrence (NR) (Fig. 3C).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The IHC results revealed significantly stronger SLC31A1 protein expression levels in tumor sections collected from ER-positive breast cancer tissues with recurrence compared to the non-recurrent samples (Fig. 3D).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The IF staining analysis indicated that post-treatment tumors from the NR group exhibited similar SLC31A1 expression levels to their pre-treatment counterparts (Fig. 3E and F).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel E",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, post-treatment tumors from non-responders with recurrence showed a marked increase in SLC31A1 expression levels compared to their pre-treatment counterparts (Fig. 3G and H).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel G",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "IF staining results indicated that SLC31A1 expression was highly elevated in metastatic tissues compared to the primary tumor tissues (Fig. 3I and J).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel I",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Data were presented as means ± SD. ⁎⁎⁎P<0.001, ⁎⁎⁎⁎P<0.0001; ns, no significant difference.SLC31A1 deficiency rescues chemosensitivity in ER-positive breast cancer cells\nSubsequently, in vitro experiments were carried out to further investigate the impact of SLC31A1 expression changes on breast cancer progression and the underlying mechanisms using the TAM-sensitive breast cancer cell lines T47D and MCF7, and the constructed TAM-resistant (TR) ER-positive breast cancer cell lines (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Initially, RT-qPCR results indicated that T47D/TR and MCF7/TR cells exhibited significantly elevated expression of SLC31A1 at the mRNA level compared to the corresponding sensitive groups (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Western blot and IF staining confirmed significantly stronger SLC31A1 protein expression levels in T47D/TR and MCF7/TR cells than in the chemosensitive cell lines (Fig. 4C and D, Supplementary Fig. 1A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "RT-qPCR and western blot results confirmed the successful knockdown of SLC31A1 in breast cancer cells (Fig. 4E and F).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "More importantly, shSLC31A1 significantly enhanced the sensitivity of T47D/TR and MCF7/TR cells to TAM treatment, as indicated by the decreased cell viability through CCK-8 analysis (Fig. 4G).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Similarly, EdU staining confirmed that SLC31A1 depletion significantly reduced the proliferative capacity of T47D/TR and MCF7/TR cells in response to TAM incubation, which was comparable to the TAM single-treatment group (Fig. 4H).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel H",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel H",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel H",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Transwell analysis demonstrated that TAM had no significant effect on the invasion of T47D/TR and MCF7/TR cells, while shSLC31A1 infection strongly inhibited the invasive ability of TAM-resistant breast cancer cells (Fig. 4I), accompanied by a marked decrease in the expression of invasive markers, including N-Cadherin, VEFG, and matrix metalloproteinase-9 (MMP9) (Supplementary Fig. 2A-C).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel I",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel I",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel I",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Data were presented as means ± SD. ⁎⁎⁎P<0.001, ⁎⁎⁎⁎P<0.0001; +++P<0.001, ++++P<0.0001 vs the TAM group; ns, no significant difference.SLC31A1 promotes the proliferation and invasion of ER-positive breast cancer cells in vitro\nTo further confirm the association between SLC31A1 and TAM resistance in ER-positive breast cancer cells, we overexpressed SLC31A1 in parental T47D and MCF7 cells, which were identified by RT-qPCR and western blot assays (Fig. 5A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As anticipated, CCK-8 analysis indicated that SLC31A1 overexpression significantly restored the proliferation of T47D and MCF7 cells compared with the oe-Vec control group (Fig. 5C).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Notably, the TAM-restricted proliferation of T47D and MCF7 cells was notably abolished upon SLC31A1 overexpression (Fig. 5D).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Similarly, oe-SLC31A1 not only strongly promoted the invasion of T47D and MCF7 cells but also rescued the invasive ability of breast cancer cells (Fig. 5E), as evidenced by the increased number of invaded cells.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Consistent with this, the suppressed expression levels of N-Cadherin, VEGF, and MMP9 in T47D and MCF7 cells by TAM were significantly reduced when SLC31A1 was overexpressed (Fig. 5F).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As shown in Fig. 6A, we found higher copper concentrations in T47D/TR and MCF7/TR cells than that of their parental cell lines.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "We discovered that 481 genes were downregulated in T47D/TR cells relative to the control ones, encompassing CPT1A (Fig. 6B), a crucial gene in mediating the FAO process [29].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Further functional enrichment analysis of these DEGs by KEGG indicated that these signals were primarily implicated in the PPAR signaling pathway, fatty acid metabolism, gap junction, endocrine resistance, and fatty acid degradation (Fig. 6C).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "GSEA based on the acquired DEGs consistently disclosed that SLC31A1 was affiliated with fatty acid β-oxidation and metabolism (Fig. 6D).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "RT-qPCR results further demonstrated that the deletion of SLC31A1 conspicuously alleviated the expression of genes specifically implicated in FAO, including CPT1A, CPT1B, ACOX1, and 3-hydroxymethylglutaryl-CoA synthase 2 (HMGCS2), but augmented the fatty acid synthesis-related genes fatty acid synthase (FASN), acetyl-CoA carboxylase (ACC), and stearoyl-CoA desaturase (SCD) (Fig. 6E).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel E",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel E",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel E",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "RT-qPCR and western blot assays indicated that T47D/TR and MCF7/TR cells manifested stronger CPT1A mRNA and protein expression levels than those of the parental breast cancer cell lines (Fig. 6F and G).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel F",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "As anticipated, higher FAO and ATP levels were detected in T47D/TR and MCF7/TR compared to the chemosensitive breast cancer cell lines (Fig. 6H and I).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel H",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Notably, CPT1A deficiency significantly enhanced the chemosensitivity of T47D/TR and MCF7/TR cells to TAM incubation by CCK-8 analysis (Fig. 6J).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel J",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel J",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel J",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "In accordance with expectation, CPT1A deletion resulted in significantly higher lipid deposition in TAM-resistant T47D and MCF7 cells (Fig. 6K), as indicated by the larger size of lipid droplets, revealing the limited FAO process.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel K",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel K",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel K",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Furthermore, PO-induced mitochondrial injury was exacerbated in T47D/TR and MCF7/TR cells transfected with siCPT1A (Fig. 6L).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel L",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel L",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel L",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Together, these results above demonstrated that SLC31A1-mediated recurrence of ER-positive breast cancer might be associated with FAO process through controlling CPT1A expression.Copper/SLC31A1 enhances CPT1A expression levels in chemoresistant breast cancer cells\nTo explore the physiological effects of copper on CPT1A expression in TAM-resistant breast cancer cells, we discovered that copper supplementation led to CPT1A expression levels in a dose-dependent manner, and importantly, SLC31A1 deletion could significantly abrogate copper-triggered increase of CPT1A in T47D/TR and MCF7/TR cell lines (Fig. 7A).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Moreover, CPT1A suppression by its specific inhibitor ETO or siCPT1A markedly mitigated CPT1A expression levels in T47D/TR and MCF7/TR cells under copper exposure (Fig. 7B).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Subsequently, we found that copper-induced CPT1A up-regulation was potently antagonized by copper chelator TTM in chemoresistant breast cancer cell lines (Fig. 7C).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "As expected, promoting SLC31A1 expression significantly enhanced CPT1A in T47D and MCF7 cells (Fig. 8A), along with higher copper concentrations (Fig. 8B).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Moreover, FAO rates and ATP levels were markedly upregulated by SLC31A1 overexpression in parental breast cancer cells (Fig. 8C and D).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel C",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Surprisingly, CCK8-analysis revealed that SLC31A1-facilitated proliferation of T47D and MCF7 cells was significantly abolished when CPT1A expression was inhibited by siCPT1A and ETO (Fig. 8E), which was validated by EdU staining (Fig. 8F and G), evidenced by the strongly decreased EdU-positive cells.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel E",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel F",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel E",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel E",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Transwell analysis further demonstrated that CPT1A expression suppression abolished the promotive effect of SLC31A1 on the invasion of breast cancer cells (Fig. 8H and I).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel H",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "In addition, in T47D and MCF7 cells overexpressing SLC31A1, CPT1A inhibition significantly reduced the FAO rates and ATP levels (Fig. 8J and K), along with diminished expression levels of CPT1A (Fig. 8L).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel J",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel L",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel L",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel L",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "As shown in Fig. 9A-C, TAM treatment had no significant effect on tumor growth compared to the control group; however, stable SLC31A1 knockdown not only significantly reduced the tumor growth rates and tumor weight, but also enhanced the response of these mice to TAM treatment, as indicated by the much lower tumor volume and weight.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "H&E staining indicated that the tumor cell density was significantly reduced in mice receiving TAM and shSLC31A1 combinatorial treatments (Fig. 9D).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "IHC staining further demonstrated that SLC31A1 deletion markedly decreased the positive expression of KI-67, CPT1A, and N-Cadherin in tumor sections, and enhanced the inhibitory effect of TAM on these molecules in mice bearing MCF7/TR tumors (Fig. 9D and E).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Furthermore, IF staining identified that SLC31A1 depletion induced higher Caspase-3 cleavage levels in tumor tissues, which were further enhanced in these mice receiving TAM plus shSLC31A1 (Fig. 9F).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Taken together, we concluded that SLC31A1 upregulation enhanced copper transportation into breast cancer cells, which drove CPT1A expression, followed by FAO elevation, thereby facilitating the proliferation, EMT process, and TAM resistance, and suppressing apoptosis in ER-positive breast cancer cells (Fig. 9G).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "In summary, our findings uncovered that SLC31A1/copper axis was a significant drug-resistant factor, which could promote the proliferation, EMT and chemoresistance but restrain apoptosis in ER-positive breast cancer through promoting the expression of CPT1A and associated FAO process (Fig. 9G).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Among these DEGs, SLC31A1, a copper transporter, was highly expressed in the recurrent tumor specimens (Fig. 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Meanwhile, a gradually increasing SLC31A1 was detected in advanced-stage tumor specimens compared to those in the early stage (Fig. 1B and C).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "To further explore the prognostic value and expression of SLC31A1, the TCGA database was analyzed, and the result demonstrated that SLC31A1 expression was significantly upregulated in breast invasive carcinoma (BRCA) samples compared to the paired normal samples (Fig. 1D).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Additionally, higher SLC31A1 expression levels predicted poorer overall survival and progress-free interval survival rates than patients with lower SLC31A1 expression levels (Fig. 1E and F).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel E",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The results in Fig. 1G showed that SLC31A1 expression was significantly up-regulated in breast tumor tissues with ≥25-75% stained cells, while its corresponding normal tissues were moderately stained or unstained.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel G",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Data were presented as means ± SD. ⁎⁎P<0.01, ⁎⁎⁎P<0.001, ⁎⁎⁎⁎P<0.0001.SLC31A1 expression levels are up-regulated in ER-positive breast cancer patients\nIn this part, we verified higher expression of SLC31A1 in BRCA tissues compared to normal tissues through TIMER analysis (Fig. 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Despite detecting a positive correlation between SLC31A1 and ERBB2 (HER2) in BRCA samples, there was no significant difference observed between SLC31A1 and HER2 in BRCA-Basal and -Her2 specimens (Fig. 2B-E).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Additionally, no significant difference was detected between SLC31A1 expression and PGR expression in BRCA-Basal and BRCA samples (Fig. 2B and C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In vitro studies further demonstrated that SLCA31A mRNA and protein expression levels were higher in ER-positive breast cancer cell lines (T47D, MCF7, BT474, ZR-75-1), while being undetectable or slightly expressed in ER-negative breast cancer cell lines (MB231, HCC1954, MB453) and the normal epithelial cell line (MCF10A) (Fig. 2F-H).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "RT-qPCR results demonstrated that SLC31A1 was highly expressed in ER-positive breast cancer specimens in comparison to the matched adjacent normal tissues (Fig. 3A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Notably, much stronger SLC31A1 gene expression levels were detected in ER-positive breast cancer samples from patients with recurrence (R) than those of the patients without recurrence (NR) (Fig. 3C).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The IHC results revealed significantly stronger SLC31A1 protein expression levels in tumor sections collected from ER-positive breast cancer tissues with recurrence compared to the non-recurrent samples (Fig. 3D).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The IF staining analysis indicated that post-treatment tumors from the NR group exhibited similar SLC31A1 expression levels to their pre-treatment counterparts (Fig. 3E and F).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel E",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, post-treatment tumors from non-responders with recurrence showed a marked increase in SLC31A1 expression levels compared to their pre-treatment counterparts (Fig. 3G and H).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel G",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "IF staining results indicated that SLC31A1 expression was highly elevated in metastatic tissues compared to the primary tumor tissues (Fig. 3I and J).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel I",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Data were presented as means ± SD. ⁎⁎⁎P<0.001, ⁎⁎⁎⁎P<0.0001; ns, no significant difference.SLC31A1 deficiency rescues chemosensitivity in ER-positive breast cancer cells\nSubsequently, in vitro experiments were carried out to further investigate the impact of SLC31A1 expression changes on breast cancer progression and the underlying mechanisms using the TAM-sensitive breast cancer cell lines T47D and MCF7, and the constructed TAM-resistant (TR) ER-positive breast cancer cell lines (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Initially, RT-qPCR results indicated that T47D/TR and MCF7/TR cells exhibited significantly elevated expression of SLC31A1 at the mRNA level compared to the corresponding sensitive groups (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Western blot and IF staining confirmed significantly stronger SLC31A1 protein expression levels in T47D/TR and MCF7/TR cells than in the chemosensitive cell lines (Fig. 4C and D, Supplementary Fig. 1A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "RT-qPCR and western blot results confirmed the successful knockdown of SLC31A1 in breast cancer cells (Fig. 4E and F).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "More importantly, shSLC31A1 significantly enhanced the sensitivity of T47D/TR and MCF7/TR cells to TAM treatment, as indicated by the decreased cell viability through CCK-8 analysis (Fig. 4G).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Similarly, EdU staining confirmed that SLC31A1 depletion significantly reduced the proliferative capacity of T47D/TR and MCF7/TR cells in response to TAM incubation, which was comparable to the TAM single-treatment group (Fig. 4H).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel H",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel H",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel H",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Transwell analysis demonstrated that TAM had no significant effect on the invasion of T47D/TR and MCF7/TR cells, while shSLC31A1 infection strongly inhibited the invasive ability of TAM-resistant breast cancer cells (Fig. 4I), accompanied by a marked decrease in the expression of invasive markers, including N-Cadherin, VEFG, and matrix metalloproteinase-9 (MMP9) (Supplementary Fig. 2A-C).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel I",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel I",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel I",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Data were presented as means ± SD. ⁎⁎⁎P<0.001, ⁎⁎⁎⁎P<0.0001; +++P<0.001, ++++P<0.0001 vs the TAM group; ns, no significant difference.SLC31A1 promotes the proliferation and invasion of ER-positive breast cancer cells in vitro\nTo further confirm the association between SLC31A1 and TAM resistance in ER-positive breast cancer cells, we overexpressed SLC31A1 in parental T47D and MCF7 cells, which were identified by RT-qPCR and western blot assays (Fig. 5A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As anticipated, CCK-8 analysis indicated that SLC31A1 overexpression significantly restored the proliferation of T47D and MCF7 cells compared with the oe-Vec control group (Fig. 5C).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Notably, the TAM-restricted proliferation of T47D and MCF7 cells was notably abolished upon SLC31A1 overexpression (Fig. 5D).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Similarly, oe-SLC31A1 not only strongly promoted the invasion of T47D and MCF7 cells but also rescued the invasive ability of breast cancer cells (Fig. 5E), as evidenced by the increased number of invaded cells.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Consistent with this, the suppressed expression levels of N-Cadherin, VEGF, and MMP9 in T47D and MCF7 cells by TAM were significantly reduced when SLC31A1 was overexpressed (Fig. 5F).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As shown in Fig. 6A, we found higher copper concentrations in T47D/TR and MCF7/TR cells than that of their parental cell lines.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "We discovered that 481 genes were downregulated in T47D/TR cells relative to the control ones, encompassing CPT1A (Fig. 6B), a crucial gene in mediating the FAO process [29].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Further functional enrichment analysis of these DEGs by KEGG indicated that these signals were primarily implicated in the PPAR signaling pathway, fatty acid metabolism, gap junction, endocrine resistance, and fatty acid degradation (Fig. 6C).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "GSEA based on the acquired DEGs consistently disclosed that SLC31A1 was affiliated with fatty acid β-oxidation and metabolism (Fig. 6D).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "RT-qPCR results further demonstrated that the deletion of SLC31A1 conspicuously alleviated the expression of genes specifically implicated in FAO, including CPT1A, CPT1B, ACOX1, and 3-hydroxymethylglutaryl-CoA synthase 2 (HMGCS2), but augmented the fatty acid synthesis-related genes fatty acid synthase (FASN), acetyl-CoA carboxylase (ACC), and stearoyl-CoA desaturase (SCD) (Fig. 6E).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel E",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel E",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel E",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "RT-qPCR and western blot assays indicated that T47D/TR and MCF7/TR cells manifested stronger CPT1A mRNA and protein expression levels than those of the parental breast cancer cell lines (Fig. 6F and G).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel F",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "As anticipated, higher FAO and ATP levels were detected in T47D/TR and MCF7/TR compared to the chemosensitive breast cancer cell lines (Fig. 6H and I).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel H",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Notably, CPT1A deficiency significantly enhanced the chemosensitivity of T47D/TR and MCF7/TR cells to TAM incubation by CCK-8 analysis (Fig. 6J).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel J",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel J",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel J",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "In accordance with expectation, CPT1A deletion resulted in significantly higher lipid deposition in TAM-resistant T47D and MCF7 cells (Fig. 6K), as indicated by the larger size of lipid droplets, revealing the limited FAO process.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel K",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel K",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel K",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Furthermore, PO-induced mitochondrial injury was exacerbated in T47D/TR and MCF7/TR cells transfected with siCPT1A (Fig. 6L).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel L",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel L",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel L",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Together, these results above demonstrated that SLC31A1-mediated recurrence of ER-positive breast cancer might be associated with FAO process through controlling CPT1A expression.Copper/SLC31A1 enhances CPT1A expression levels in chemoresistant breast cancer cells\nTo explore the physiological effects of copper on CPT1A expression in TAM-resistant breast cancer cells, we discovered that copper supplementation led to CPT1A expression levels in a dose-dependent manner, and importantly, SLC31A1 deletion could significantly abrogate copper-triggered increase of CPT1A in T47D/TR and MCF7/TR cell lines (Fig. 7A).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Moreover, CPT1A suppression by its specific inhibitor ETO or siCPT1A markedly mitigated CPT1A expression levels in T47D/TR and MCF7/TR cells under copper exposure (Fig. 7B).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Subsequently, we found that copper-induced CPT1A up-regulation was potently antagonized by copper chelator TTM in chemoresistant breast cancer cell lines (Fig. 7C).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "As expected, promoting SLC31A1 expression significantly enhanced CPT1A in T47D and MCF7 cells (Fig. 8A), along with higher copper concentrations (Fig. 8B).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Moreover, FAO rates and ATP levels were markedly upregulated by SLC31A1 overexpression in parental breast cancer cells (Fig. 8C and D).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel C",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Surprisingly, CCK8-analysis revealed that SLC31A1-facilitated proliferation of T47D and MCF7 cells was significantly abolished when CPT1A expression was inhibited by siCPT1A and ETO (Fig. 8E), which was validated by EdU staining (Fig. 8F and G), evidenced by the strongly decreased EdU-positive cells.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel E",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel F",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel E",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel E",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Transwell analysis further demonstrated that CPT1A expression suppression abolished the promotive effect of SLC31A1 on the invasion of breast cancer cells (Fig. 8H and I).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel H",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "In addition, in T47D and MCF7 cells overexpressing SLC31A1, CPT1A inhibition significantly reduced the FAO rates and ATP levels (Fig. 8J and K), along with diminished expression levels of CPT1A (Fig. 8L).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel J",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel L",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel L",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel L",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "As shown in Fig. 9A-C, TAM treatment had no significant effect on tumor growth compared to the control group; however, stable SLC31A1 knockdown not only significantly reduced the tumor growth rates and tumor weight, but also enhanced the response of these mice to TAM treatment, as indicated by the much lower tumor volume and weight.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "H&E staining indicated that the tumor cell density was significantly reduced in mice receiving TAM and shSLC31A1 combinatorial treatments (Fig. 9D).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "IHC staining further demonstrated that SLC31A1 deletion markedly decreased the positive expression of KI-67, CPT1A, and N-Cadherin in tumor sections, and enhanced the inhibitory effect of TAM on these molecules in mice bearing MCF7/TR tumors (Fig. 9D and E).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Furthermore, IF staining identified that SLC31A1 depletion induced higher Caspase-3 cleavage levels in tumor tissues, which were further enhanced in these mice receiving TAM plus shSLC31A1 (Fig. 9F).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Taken together, we concluded that SLC31A1 upregulation enhanced copper transportation into breast cancer cells, which drove CPT1A expression, followed by FAO elevation, thereby facilitating the proliferation, EMT process, and TAM resistance, and suppressing apoptosis in ER-positive breast cancer cells (Fig. 9G).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "In summary, our findings uncovered that SLC31A1/copper axis was a significant drug-resistant factor, which could promote the proliferation, EMT and chemoresistance but restrain apoptosis in ER-positive breast cancer through promoting the expression of CPT1A and associated FAO process (Fig. 9G).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Among these DEGs, SLC31A1, a copper transporter, was highly expressed in the recurrent tumor specimens (Fig. 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Meanwhile, a gradually increasing SLC31A1 was detected in advanced-stage tumor specimens compared to those in the early stage (Fig. 1B and C).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "To further explore the prognostic value and expression of SLC31A1, the TCGA database was analyzed, and the result demonstrated that SLC31A1 expression was significantly upregulated in breast invasive carcinoma (BRCA) samples compared to the paired normal samples (Fig. 1D).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Additionally, higher SLC31A1 expression levels predicted poorer overall survival and progress-free interval survival rates than patients with lower SLC31A1 expression levels (Fig. 1E and F).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel E",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The results in Fig. 1G showed that SLC31A1 expression was significantly up-regulated in breast tumor tissues with ≥25-75% stained cells, while its corresponding normal tissues were moderately stained or unstained.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel G",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Data were presented as means ± SD. ⁎⁎P<0.01, ⁎⁎⁎P<0.001, ⁎⁎⁎⁎P<0.0001.SLC31A1 expression levels are up-regulated in ER-positive breast cancer patients\nIn this part, we verified higher expression of SLC31A1 in BRCA tissues compared to normal tissues through TIMER analysis (Fig. 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Despite detecting a positive correlation between SLC31A1 and ERBB2 (HER2) in BRCA samples, there was no significant difference observed between SLC31A1 and HER2 in BRCA-Basal and -Her2 specimens (Fig. 2B-E).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Additionally, no significant difference was detected between SLC31A1 expression and PGR expression in BRCA-Basal and BRCA samples (Fig. 2B and C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In vitro studies further demonstrated that SLCA31A mRNA and protein expression levels were higher in ER-positive breast cancer cell lines (T47D, MCF7, BT474, ZR-75-1), while being undetectable or slightly expressed in ER-negative breast cancer cell lines (MB231, HCC1954, MB453) and the normal epithelial cell line (MCF10A) (Fig. 2F-H).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "RT-qPCR results demonstrated that SLC31A1 was highly expressed in ER-positive breast cancer specimens in comparison to the matched adjacent normal tissues (Fig. 3A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Notably, much stronger SLC31A1 gene expression levels were detected in ER-positive breast cancer samples from patients with recurrence (R) than those of the patients without recurrence (NR) (Fig. 3C).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The IHC results revealed significantly stronger SLC31A1 protein expression levels in tumor sections collected from ER-positive breast cancer tissues with recurrence compared to the non-recurrent samples (Fig. 3D).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The IF staining analysis indicated that post-treatment tumors from the NR group exhibited similar SLC31A1 expression levels to their pre-treatment counterparts (Fig. 3E and F).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel E",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, post-treatment tumors from non-responders with recurrence showed a marked increase in SLC31A1 expression levels compared to their pre-treatment counterparts (Fig. 3G and H).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel G",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "IF staining results indicated that SLC31A1 expression was highly elevated in metastatic tissues compared to the primary tumor tissues (Fig. 3I and J).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel I",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Data were presented as means ± SD. ⁎⁎⁎P<0.001, ⁎⁎⁎⁎P<0.0001; ns, no significant difference.SLC31A1 deficiency rescues chemosensitivity in ER-positive breast cancer cells\nSubsequently, in vitro experiments were carried out to further investigate the impact of SLC31A1 expression changes on breast cancer progression and the underlying mechanisms using the TAM-sensitive breast cancer cell lines T47D and MCF7, and the constructed TAM-resistant (TR) ER-positive breast cancer cell lines (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Initially, RT-qPCR results indicated that T47D/TR and MCF7/TR cells exhibited significantly elevated expression of SLC31A1 at the mRNA level compared to the corresponding sensitive groups (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Western blot and IF staining confirmed significantly stronger SLC31A1 protein expression levels in T47D/TR and MCF7/TR cells than in the chemosensitive cell lines (Fig. 4C and D, Supplementary Fig. 1A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "RT-qPCR and western blot results confirmed the successful knockdown of SLC31A1 in breast cancer cells (Fig. 4E and F).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "More importantly, shSLC31A1 significantly enhanced the sensitivity of T47D/TR and MCF7/TR cells to TAM treatment, as indicated by the decreased cell viability through CCK-8 analysis (Fig. 4G).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Similarly, EdU staining confirmed that SLC31A1 depletion significantly reduced the proliferative capacity of T47D/TR and MCF7/TR cells in response to TAM incubation, which was comparable to the TAM single-treatment group (Fig. 4H).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel H",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel H",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel H",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Transwell analysis demonstrated that TAM had no significant effect on the invasion of T47D/TR and MCF7/TR cells, while shSLC31A1 infection strongly inhibited the invasive ability of TAM-resistant breast cancer cells (Fig. 4I), accompanied by a marked decrease in the expression of invasive markers, including N-Cadherin, VEFG, and matrix metalloproteinase-9 (MMP9) (Supplementary Fig. 2A-C).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel I",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel I",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel I",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Data were presented as means ± SD. ⁎⁎⁎P<0.001, ⁎⁎⁎⁎P<0.0001; +++P<0.001, ++++P<0.0001 vs the TAM group; ns, no significant difference.SLC31A1 promotes the proliferation and invasion of ER-positive breast cancer cells in vitro\nTo further confirm the association between SLC31A1 and TAM resistance in ER-positive breast cancer cells, we overexpressed SLC31A1 in parental T47D and MCF7 cells, which were identified by RT-qPCR and western blot assays (Fig. 5A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As anticipated, CCK-8 analysis indicated that SLC31A1 overexpression significantly restored the proliferation of T47D and MCF7 cells compared with the oe-Vec control group (Fig. 5C).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Notably, the TAM-restricted proliferation of T47D and MCF7 cells was notably abolished upon SLC31A1 overexpression (Fig. 5D).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Similarly, oe-SLC31A1 not only strongly promoted the invasion of T47D and MCF7 cells but also rescued the invasive ability of breast cancer cells (Fig. 5E), as evidenced by the increased number of invaded cells.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Consistent with this, the suppressed expression levels of N-Cadherin, VEGF, and MMP9 in T47D and MCF7 cells by TAM were significantly reduced when SLC31A1 was overexpressed (Fig. 5F).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As shown in Fig. 6A, we found higher copper concentrations in T47D/TR and MCF7/TR cells than that of their parental cell lines.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "We discovered that 481 genes were downregulated in T47D/TR cells relative to the control ones, encompassing CPT1A (Fig. 6B), a crucial gene in mediating the FAO process [29].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Further functional enrichment analysis of these DEGs by KEGG indicated that these signals were primarily implicated in the PPAR signaling pathway, fatty acid metabolism, gap junction, endocrine resistance, and fatty acid degradation (Fig. 6C).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "GSEA based on the acquired DEGs consistently disclosed that SLC31A1 was affiliated with fatty acid β-oxidation and metabolism (Fig. 6D).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "RT-qPCR results further demonstrated that the deletion of SLC31A1 conspicuously alleviated the expression of genes specifically implicated in FAO, including CPT1A, CPT1B, ACOX1, and 3-hydroxymethylglutaryl-CoA synthase 2 (HMGCS2), but augmented the fatty acid synthesis-related genes fatty acid synthase (FASN), acetyl-CoA carboxylase (ACC), and stearoyl-CoA desaturase (SCD) (Fig. 6E).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel E",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel E",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel E",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "RT-qPCR and western blot assays indicated that T47D/TR and MCF7/TR cells manifested stronger CPT1A mRNA and protein expression levels than those of the parental breast cancer cell lines (Fig. 6F and G).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel F",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "As anticipated, higher FAO and ATP levels were detected in T47D/TR and MCF7/TR compared to the chemosensitive breast cancer cell lines (Fig. 6H and I).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel H",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Notably, CPT1A deficiency significantly enhanced the chemosensitivity of T47D/TR and MCF7/TR cells to TAM incubation by CCK-8 analysis (Fig. 6J).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel J",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel J",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel J",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "In accordance with expectation, CPT1A deletion resulted in significantly higher lipid deposition in TAM-resistant T47D and MCF7 cells (Fig. 6K), as indicated by the larger size of lipid droplets, revealing the limited FAO process.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel K",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel K",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel K",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Furthermore, PO-induced mitochondrial injury was exacerbated in T47D/TR and MCF7/TR cells transfected with siCPT1A (Fig. 6L).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel L",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel L",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel L",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Together, these results above demonstrated that SLC31A1-mediated recurrence of ER-positive breast cancer might be associated with FAO process through controlling CPT1A expression.Copper/SLC31A1 enhances CPT1A expression levels in chemoresistant breast cancer cells\nTo explore the physiological effects of copper on CPT1A expression in TAM-resistant breast cancer cells, we discovered that copper supplementation led to CPT1A expression levels in a dose-dependent manner, and importantly, SLC31A1 deletion could significantly abrogate copper-triggered increase of CPT1A in T47D/TR and MCF7/TR cell lines (Fig. 7A).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Moreover, CPT1A suppression by its specific inhibitor ETO or siCPT1A markedly mitigated CPT1A expression levels in T47D/TR and MCF7/TR cells under copper exposure (Fig. 7B).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Subsequently, we found that copper-induced CPT1A up-regulation was potently antagonized by copper chelator TTM in chemoresistant breast cancer cell lines (Fig. 7C).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "As expected, promoting SLC31A1 expression significantly enhanced CPT1A in T47D and MCF7 cells (Fig. 8A), along with higher copper concentrations (Fig. 8B).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Moreover, FAO rates and ATP levels were markedly upregulated by SLC31A1 overexpression in parental breast cancer cells (Fig. 8C and D).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel C",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Surprisingly, CCK8-analysis revealed that SLC31A1-facilitated proliferation of T47D and MCF7 cells was significantly abolished when CPT1A expression was inhibited by siCPT1A and ETO (Fig. 8E), which was validated by EdU staining (Fig. 8F and G), evidenced by the strongly decreased EdU-positive cells.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel E",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel F",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel E",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel E",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Transwell analysis further demonstrated that CPT1A expression suppression abolished the promotive effect of SLC31A1 on the invasion of breast cancer cells (Fig. 8H and I).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel H",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "In addition, in T47D and MCF7 cells overexpressing SLC31A1, CPT1A inhibition significantly reduced the FAO rates and ATP levels (Fig. 8J and K), along with diminished expression levels of CPT1A (Fig. 8L).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel J",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel L",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel L",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel L",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "As shown in Fig. 9A-C, TAM treatment had no significant effect on tumor growth compared to the control group; however, stable SLC31A1 knockdown not only significantly reduced the tumor growth rates and tumor weight, but also enhanced the response of these mice to TAM treatment, as indicated by the much lower tumor volume and weight.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "H&E staining indicated that the tumor cell density was significantly reduced in mice receiving TAM and shSLC31A1 combinatorial treatments (Fig. 9D).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "IHC staining further demonstrated that SLC31A1 deletion markedly decreased the positive expression of KI-67, CPT1A, and N-Cadherin in tumor sections, and enhanced the inhibitory effect of TAM on these molecules in mice bearing MCF7/TR tumors (Fig. 9D and E).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Furthermore, IF staining identified that SLC31A1 depletion induced higher Caspase-3 cleavage levels in tumor tissues, which were further enhanced in these mice receiving TAM plus shSLC31A1 (Fig. 9F).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Taken together, we concluded that SLC31A1 upregulation enhanced copper transportation into breast cancer cells, which drove CPT1A expression, followed by FAO elevation, thereby facilitating the proliferation, EMT process, and TAM resistance, and suppressing apoptosis in ER-positive breast cancer cells (Fig. 9G).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "In summary, our findings uncovered that SLC31A1/copper axis was a significant drug-resistant factor, which could promote the proliferation, EMT and chemoresistance but restrain apoptosis in ER-positive breast cancer through promoting the expression of CPT1A and associated FAO process (Fig. 9G).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Among these DEGs, SLC31A1, a copper transporter, was highly expressed in the recurrent tumor specimens (Fig. 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Meanwhile, a gradually increasing SLC31A1 was detected in advanced-stage tumor specimens compared to those in the early stage (Fig. 1B and C).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "To further explore the prognostic value and expression of SLC31A1, the TCGA database was analyzed, and the result demonstrated that SLC31A1 expression was significantly upregulated in breast invasive carcinoma (BRCA) samples compared to the paired normal samples (Fig. 1D).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Additionally, higher SLC31A1 expression levels predicted poorer overall survival and progress-free interval survival rates than patients with lower SLC31A1 expression levels (Fig. 1E and F).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel E",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The results in Fig. 1G showed that SLC31A1 expression was significantly up-regulated in breast tumor tissues with ≥25-75% stained cells, while its corresponding normal tissues were moderately stained or unstained.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel G",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Data were presented as means ± SD. ⁎⁎P<0.01, ⁎⁎⁎P<0.001, ⁎⁎⁎⁎P<0.0001.SLC31A1 expression levels are up-regulated in ER-positive breast cancer patients\nIn this part, we verified higher expression of SLC31A1 in BRCA tissues compared to normal tissues through TIMER analysis (Fig. 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Despite detecting a positive correlation between SLC31A1 and ERBB2 (HER2) in BRCA samples, there was no significant difference observed between SLC31A1 and HER2 in BRCA-Basal and -Her2 specimens (Fig. 2B-E).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Additionally, no significant difference was detected between SLC31A1 expression and PGR expression in BRCA-Basal and BRCA samples (Fig. 2B and C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In vitro studies further demonstrated that SLCA31A mRNA and protein expression levels were higher in ER-positive breast cancer cell lines (T47D, MCF7, BT474, ZR-75-1), while being undetectable or slightly expressed in ER-negative breast cancer cell lines (MB231, HCC1954, MB453) and the normal epithelial cell line (MCF10A) (Fig. 2F-H).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "RT-qPCR results demonstrated that SLC31A1 was highly expressed in ER-positive breast cancer specimens in comparison to the matched adjacent normal tissues (Fig. 3A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Notably, much stronger SLC31A1 gene expression levels were detected in ER-positive breast cancer samples from patients with recurrence (R) than those of the patients without recurrence (NR) (Fig. 3C).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The IHC results revealed significantly stronger SLC31A1 protein expression levels in tumor sections collected from ER-positive breast cancer tissues with recurrence compared to the non-recurrent samples (Fig. 3D).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The IF staining analysis indicated that post-treatment tumors from the NR group exhibited similar SLC31A1 expression levels to their pre-treatment counterparts (Fig. 3E and F).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel E",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, post-treatment tumors from non-responders with recurrence showed a marked increase in SLC31A1 expression levels compared to their pre-treatment counterparts (Fig. 3G and H).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel G",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "IF staining results indicated that SLC31A1 expression was highly elevated in metastatic tissues compared to the primary tumor tissues (Fig. 3I and J).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel I",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Data were presented as means ± SD. ⁎⁎⁎P<0.001, ⁎⁎⁎⁎P<0.0001; ns, no significant difference.SLC31A1 deficiency rescues chemosensitivity in ER-positive breast cancer cells\nSubsequently, in vitro experiments were carried out to further investigate the impact of SLC31A1 expression changes on breast cancer progression and the underlying mechanisms using the TAM-sensitive breast cancer cell lines T47D and MCF7, and the constructed TAM-resistant (TR) ER-positive breast cancer cell lines (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Initially, RT-qPCR results indicated that T47D/TR and MCF7/TR cells exhibited significantly elevated expression of SLC31A1 at the mRNA level compared to the corresponding sensitive groups (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Western blot and IF staining confirmed significantly stronger SLC31A1 protein expression levels in T47D/TR and MCF7/TR cells than in the chemosensitive cell lines (Fig. 4C and D, Supplementary Fig. 1A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "RT-qPCR and western blot results confirmed the successful knockdown of SLC31A1 in breast cancer cells (Fig. 4E and F).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "More importantly, shSLC31A1 significantly enhanced the sensitivity of T47D/TR and MCF7/TR cells to TAM treatment, as indicated by the decreased cell viability through CCK-8 analysis (Fig. 4G).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Similarly, EdU staining confirmed that SLC31A1 depletion significantly reduced the proliferative capacity of T47D/TR and MCF7/TR cells in response to TAM incubation, which was comparable to the TAM single-treatment group (Fig. 4H).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel H",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel H",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel H",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Transwell analysis demonstrated that TAM had no significant effect on the invasion of T47D/TR and MCF7/TR cells, while shSLC31A1 infection strongly inhibited the invasive ability of TAM-resistant breast cancer cells (Fig. 4I), accompanied by a marked decrease in the expression of invasive markers, including N-Cadherin, VEFG, and matrix metalloproteinase-9 (MMP9) (Supplementary Fig. 2A-C).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel I",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel I",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel I",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Data were presented as means ± SD. ⁎⁎⁎P<0.001, ⁎⁎⁎⁎P<0.0001; +++P<0.001, ++++P<0.0001 vs the TAM group; ns, no significant difference.SLC31A1 promotes the proliferation and invasion of ER-positive breast cancer cells in vitro\nTo further confirm the association between SLC31A1 and TAM resistance in ER-positive breast cancer cells, we overexpressed SLC31A1 in parental T47D and MCF7 cells, which were identified by RT-qPCR and western blot assays (Fig. 5A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As anticipated, CCK-8 analysis indicated that SLC31A1 overexpression significantly restored the proliferation of T47D and MCF7 cells compared with the oe-Vec control group (Fig. 5C).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Notably, the TAM-restricted proliferation of T47D and MCF7 cells was notably abolished upon SLC31A1 overexpression (Fig. 5D).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Similarly, oe-SLC31A1 not only strongly promoted the invasion of T47D and MCF7 cells but also rescued the invasive ability of breast cancer cells (Fig. 5E), as evidenced by the increased number of invaded cells.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Consistent with this, the suppressed expression levels of N-Cadherin, VEGF, and MMP9 in T47D and MCF7 cells by TAM were significantly reduced when SLC31A1 was overexpressed (Fig. 5F).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As shown in Fig. 6A, we found higher copper concentrations in T47D/TR and MCF7/TR cells than that of their parental cell lines.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "We discovered that 481 genes were downregulated in T47D/TR cells relative to the control ones, encompassing CPT1A (Fig. 6B), a crucial gene in mediating the FAO process [29].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Further functional enrichment analysis of these DEGs by KEGG indicated that these signals were primarily implicated in the PPAR signaling pathway, fatty acid metabolism, gap junction, endocrine resistance, and fatty acid degradation (Fig. 6C).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "GSEA based on the acquired DEGs consistently disclosed that SLC31A1 was affiliated with fatty acid β-oxidation and metabolism (Fig. 6D).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "RT-qPCR results further demonstrated that the deletion of SLC31A1 conspicuously alleviated the expression of genes specifically implicated in FAO, including CPT1A, CPT1B, ACOX1, and 3-hydroxymethylglutaryl-CoA synthase 2 (HMGCS2), but augmented the fatty acid synthesis-related genes fatty acid synthase (FASN), acetyl-CoA carboxylase (ACC), and stearoyl-CoA desaturase (SCD) (Fig. 6E).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel E",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel E",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel E",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "RT-qPCR and western blot assays indicated that T47D/TR and MCF7/TR cells manifested stronger CPT1A mRNA and protein expression levels than those of the parental breast cancer cell lines (Fig. 6F and G).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel F",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "As anticipated, higher FAO and ATP levels were detected in T47D/TR and MCF7/TR compared to the chemosensitive breast cancer cell lines (Fig. 6H and I).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel H",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Notably, CPT1A deficiency significantly enhanced the chemosensitivity of T47D/TR and MCF7/TR cells to TAM incubation by CCK-8 analysis (Fig. 6J).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel J",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel J",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel J",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "In accordance with expectation, CPT1A deletion resulted in significantly higher lipid deposition in TAM-resistant T47D and MCF7 cells (Fig. 6K), as indicated by the larger size of lipid droplets, revealing the limited FAO process.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel K",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel K",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel K",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Furthermore, PO-induced mitochondrial injury was exacerbated in T47D/TR and MCF7/TR cells transfected with siCPT1A (Fig. 6L).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel L",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel L",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel L",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Together, these results above demonstrated that SLC31A1-mediated recurrence of ER-positive breast cancer might be associated with FAO process through controlling CPT1A expression.Copper/SLC31A1 enhances CPT1A expression levels in chemoresistant breast cancer cells\nTo explore the physiological effects of copper on CPT1A expression in TAM-resistant breast cancer cells, we discovered that copper supplementation led to CPT1A expression levels in a dose-dependent manner, and importantly, SLC31A1 deletion could significantly abrogate copper-triggered increase of CPT1A in T47D/TR and MCF7/TR cell lines (Fig. 7A).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Moreover, CPT1A suppression by its specific inhibitor ETO or siCPT1A markedly mitigated CPT1A expression levels in T47D/TR and MCF7/TR cells under copper exposure (Fig. 7B).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Subsequently, we found that copper-induced CPT1A up-regulation was potently antagonized by copper chelator TTM in chemoresistant breast cancer cell lines (Fig. 7C).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "As expected, promoting SLC31A1 expression significantly enhanced CPT1A in T47D and MCF7 cells (Fig. 8A), along with higher copper concentrations (Fig. 8B).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Moreover, FAO rates and ATP levels were markedly upregulated by SLC31A1 overexpression in parental breast cancer cells (Fig. 8C and D).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel C",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Surprisingly, CCK8-analysis revealed that SLC31A1-facilitated proliferation of T47D and MCF7 cells was significantly abolished when CPT1A expression was inhibited by siCPT1A and ETO (Fig. 8E), which was validated by EdU staining (Fig. 8F and G), evidenced by the strongly decreased EdU-positive cells.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel E",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel F",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel E",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel E",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Transwell analysis further demonstrated that CPT1A expression suppression abolished the promotive effect of SLC31A1 on the invasion of breast cancer cells (Fig. 8H and I).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel H",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "In addition, in T47D and MCF7 cells overexpressing SLC31A1, CPT1A inhibition significantly reduced the FAO rates and ATP levels (Fig. 8J and K), along with diminished expression levels of CPT1A (Fig. 8L).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel J",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel L",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel L",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel L",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "As shown in Fig. 9A-C, TAM treatment had no significant effect on tumor growth compared to the control group; however, stable SLC31A1 knockdown not only significantly reduced the tumor growth rates and tumor weight, but also enhanced the response of these mice to TAM treatment, as indicated by the much lower tumor volume and weight.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "H&E staining indicated that the tumor cell density was significantly reduced in mice receiving TAM and shSLC31A1 combinatorial treatments (Fig. 9D).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "IHC staining further demonstrated that SLC31A1 deletion markedly decreased the positive expression of KI-67, CPT1A, and N-Cadherin in tumor sections, and enhanced the inhibitory effect of TAM on these molecules in mice bearing MCF7/TR tumors (Fig. 9D and E).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Furthermore, IF staining identified that SLC31A1 depletion induced higher Caspase-3 cleavage levels in tumor tissues, which were further enhanced in these mice receiving TAM plus shSLC31A1 (Fig. 9F).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Taken together, we concluded that SLC31A1 upregulation enhanced copper transportation into breast cancer cells, which drove CPT1A expression, followed by FAO elevation, thereby facilitating the proliferation, EMT process, and TAM resistance, and suppressing apoptosis in ER-positive breast cancer cells (Fig. 9G).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "In summary, our findings uncovered that SLC31A1/copper axis was a significant drug-resistant factor, which could promote the proliferation, EMT and chemoresistance but restrain apoptosis in ER-positive breast cancer through promoting the expression of CPT1A and associated FAO process (Fig. 9G).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Among these DEGs, SLC31A1, a copper transporter, was highly expressed in the recurrent tumor specimens (Fig. 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Meanwhile, a gradually increasing SLC31A1 was detected in advanced-stage tumor specimens compared to those in the early stage (Fig. 1B and C).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "To further explore the prognostic value and expression of SLC31A1, the TCGA database was analyzed, and the result demonstrated that SLC31A1 expression was significantly upregulated in breast invasive carcinoma (BRCA) samples compared to the paired normal samples (Fig. 1D).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Additionally, higher SLC31A1 expression levels predicted poorer overall survival and progress-free interval survival rates than patients with lower SLC31A1 expression levels (Fig. 1E and F).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel E",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The results in Fig. 1G showed that SLC31A1 expression was significantly up-regulated in breast tumor tissues with ≥25-75% stained cells, while its corresponding normal tissues were moderately stained or unstained.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel G",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Data were presented as means ± SD. ⁎⁎P<0.01, ⁎⁎⁎P<0.001, ⁎⁎⁎⁎P<0.0001.SLC31A1 expression levels are up-regulated in ER-positive breast cancer patients\nIn this part, we verified higher expression of SLC31A1 in BRCA tissues compared to normal tissues through TIMER analysis (Fig. 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Despite detecting a positive correlation between SLC31A1 and ERBB2 (HER2) in BRCA samples, there was no significant difference observed between SLC31A1 and HER2 in BRCA-Basal and -Her2 specimens (Fig. 2B-E).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Additionally, no significant difference was detected between SLC31A1 expression and PGR expression in BRCA-Basal and BRCA samples (Fig. 2B and C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In vitro studies further demonstrated that SLCA31A mRNA and protein expression levels were higher in ER-positive breast cancer cell lines (T47D, MCF7, BT474, ZR-75-1), while being undetectable or slightly expressed in ER-negative breast cancer cell lines (MB231, HCC1954, MB453) and the normal epithelial cell line (MCF10A) (Fig. 2F-H).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "RT-qPCR results demonstrated that SLC31A1 was highly expressed in ER-positive breast cancer specimens in comparison to the matched adjacent normal tissues (Fig. 3A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Notably, much stronger SLC31A1 gene expression levels were detected in ER-positive breast cancer samples from patients with recurrence (R) than those of the patients without recurrence (NR) (Fig. 3C).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The IHC results revealed significantly stronger SLC31A1 protein expression levels in tumor sections collected from ER-positive breast cancer tissues with recurrence compared to the non-recurrent samples (Fig. 3D).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The IF staining analysis indicated that post-treatment tumors from the NR group exhibited similar SLC31A1 expression levels to their pre-treatment counterparts (Fig. 3E and F).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel E",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, post-treatment tumors from non-responders with recurrence showed a marked increase in SLC31A1 expression levels compared to their pre-treatment counterparts (Fig. 3G and H).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel G",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "IF staining results indicated that SLC31A1 expression was highly elevated in metastatic tissues compared to the primary tumor tissues (Fig. 3I and J).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel I",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Data were presented as means ± SD. ⁎⁎⁎P<0.001, ⁎⁎⁎⁎P<0.0001; ns, no significant difference.SLC31A1 deficiency rescues chemosensitivity in ER-positive breast cancer cells\nSubsequently, in vitro experiments were carried out to further investigate the impact of SLC31A1 expression changes on breast cancer progression and the underlying mechanisms using the TAM-sensitive breast cancer cell lines T47D and MCF7, and the constructed TAM-resistant (TR) ER-positive breast cancer cell lines (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Initially, RT-qPCR results indicated that T47D/TR and MCF7/TR cells exhibited significantly elevated expression of SLC31A1 at the mRNA level compared to the corresponding sensitive groups (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Western blot and IF staining confirmed significantly stronger SLC31A1 protein expression levels in T47D/TR and MCF7/TR cells than in the chemosensitive cell lines (Fig. 4C and D, Supplementary Fig. 1A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "RT-qPCR and western blot results confirmed the successful knockdown of SLC31A1 in breast cancer cells (Fig. 4E and F).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "More importantly, shSLC31A1 significantly enhanced the sensitivity of T47D/TR and MCF7/TR cells to TAM treatment, as indicated by the decreased cell viability through CCK-8 analysis (Fig. 4G).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Similarly, EdU staining confirmed that SLC31A1 depletion significantly reduced the proliferative capacity of T47D/TR and MCF7/TR cells in response to TAM incubation, which was comparable to the TAM single-treatment group (Fig. 4H).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel H",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel H",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel H",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Transwell analysis demonstrated that TAM had no significant effect on the invasion of T47D/TR and MCF7/TR cells, while shSLC31A1 infection strongly inhibited the invasive ability of TAM-resistant breast cancer cells (Fig. 4I), accompanied by a marked decrease in the expression of invasive markers, including N-Cadherin, VEFG, and matrix metalloproteinase-9 (MMP9) (Supplementary Fig. 2A-C).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel I",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel I",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel I",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Data were presented as means ± SD. ⁎⁎⁎P<0.001, ⁎⁎⁎⁎P<0.0001; +++P<0.001, ++++P<0.0001 vs the TAM group; ns, no significant difference.SLC31A1 promotes the proliferation and invasion of ER-positive breast cancer cells in vitro\nTo further confirm the association between SLC31A1 and TAM resistance in ER-positive breast cancer cells, we overexpressed SLC31A1 in parental T47D and MCF7 cells, which were identified by RT-qPCR and western blot assays (Fig. 5A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As anticipated, CCK-8 analysis indicated that SLC31A1 overexpression significantly restored the proliferation of T47D and MCF7 cells compared with the oe-Vec control group (Fig. 5C).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Notably, the TAM-restricted proliferation of T47D and MCF7 cells was notably abolished upon SLC31A1 overexpression (Fig. 5D).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Similarly, oe-SLC31A1 not only strongly promoted the invasion of T47D and MCF7 cells but also rescued the invasive ability of breast cancer cells (Fig. 5E), as evidenced by the increased number of invaded cells.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Consistent with this, the suppressed expression levels of N-Cadherin, VEGF, and MMP9 in T47D and MCF7 cells by TAM were significantly reduced when SLC31A1 was overexpressed (Fig. 5F).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As shown in Fig. 6A, we found higher copper concentrations in T47D/TR and MCF7/TR cells than that of their parental cell lines.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "We discovered that 481 genes were downregulated in T47D/TR cells relative to the control ones, encompassing CPT1A (Fig. 6B), a crucial gene in mediating the FAO process [29].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Further functional enrichment analysis of these DEGs by KEGG indicated that these signals were primarily implicated in the PPAR signaling pathway, fatty acid metabolism, gap junction, endocrine resistance, and fatty acid degradation (Fig. 6C).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "GSEA based on the acquired DEGs consistently disclosed that SLC31A1 was affiliated with fatty acid β-oxidation and metabolism (Fig. 6D).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "RT-qPCR results further demonstrated that the deletion of SLC31A1 conspicuously alleviated the expression of genes specifically implicated in FAO, including CPT1A, CPT1B, ACOX1, and 3-hydroxymethylglutaryl-CoA synthase 2 (HMGCS2), but augmented the fatty acid synthesis-related genes fatty acid synthase (FASN), acetyl-CoA carboxylase (ACC), and stearoyl-CoA desaturase (SCD) (Fig. 6E).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel E",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel E",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel E",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "RT-qPCR and western blot assays indicated that T47D/TR and MCF7/TR cells manifested stronger CPT1A mRNA and protein expression levels than those of the parental breast cancer cell lines (Fig. 6F and G).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel F",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "As anticipated, higher FAO and ATP levels were detected in T47D/TR and MCF7/TR compared to the chemosensitive breast cancer cell lines (Fig. 6H and I).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel H",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Notably, CPT1A deficiency significantly enhanced the chemosensitivity of T47D/TR and MCF7/TR cells to TAM incubation by CCK-8 analysis (Fig. 6J).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel J",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel J",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel J",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "In accordance with expectation, CPT1A deletion resulted in significantly higher lipid deposition in TAM-resistant T47D and MCF7 cells (Fig. 6K), as indicated by the larger size of lipid droplets, revealing the limited FAO process.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel K",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel K",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel K",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Furthermore, PO-induced mitochondrial injury was exacerbated in T47D/TR and MCF7/TR cells transfected with siCPT1A (Fig. 6L).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel L",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel L",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel L",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Together, these results above demonstrated that SLC31A1-mediated recurrence of ER-positive breast cancer might be associated with FAO process through controlling CPT1A expression.Copper/SLC31A1 enhances CPT1A expression levels in chemoresistant breast cancer cells\nTo explore the physiological effects of copper on CPT1A expression in TAM-resistant breast cancer cells, we discovered that copper supplementation led to CPT1A expression levels in a dose-dependent manner, and importantly, SLC31A1 deletion could significantly abrogate copper-triggered increase of CPT1A in T47D/TR and MCF7/TR cell lines (Fig. 7A).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Moreover, CPT1A suppression by its specific inhibitor ETO or siCPT1A markedly mitigated CPT1A expression levels in T47D/TR and MCF7/TR cells under copper exposure (Fig. 7B).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Subsequently, we found that copper-induced CPT1A up-regulation was potently antagonized by copper chelator TTM in chemoresistant breast cancer cell lines (Fig. 7C).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "As expected, promoting SLC31A1 expression significantly enhanced CPT1A in T47D and MCF7 cells (Fig. 8A), along with higher copper concentrations (Fig. 8B).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Moreover, FAO rates and ATP levels were markedly upregulated by SLC31A1 overexpression in parental breast cancer cells (Fig. 8C and D).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel C",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Surprisingly, CCK8-analysis revealed that SLC31A1-facilitated proliferation of T47D and MCF7 cells was significantly abolished when CPT1A expression was inhibited by siCPT1A and ETO (Fig. 8E), which was validated by EdU staining (Fig. 8F and G), evidenced by the strongly decreased EdU-positive cells.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel E",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel F",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel E",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel E",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Transwell analysis further demonstrated that CPT1A expression suppression abolished the promotive effect of SLC31A1 on the invasion of breast cancer cells (Fig. 8H and I).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel H",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "In addition, in T47D and MCF7 cells overexpressing SLC31A1, CPT1A inhibition significantly reduced the FAO rates and ATP levels (Fig. 8J and K), along with diminished expression levels of CPT1A (Fig. 8L).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel J",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel L",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel L",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel L",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "As shown in Fig. 9A-C, TAM treatment had no significant effect on tumor growth compared to the control group; however, stable SLC31A1 knockdown not only significantly reduced the tumor growth rates and tumor weight, but also enhanced the response of these mice to TAM treatment, as indicated by the much lower tumor volume and weight.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "H&E staining indicated that the tumor cell density was significantly reduced in mice receiving TAM and shSLC31A1 combinatorial treatments (Fig. 9D).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "IHC staining further demonstrated that SLC31A1 deletion markedly decreased the positive expression of KI-67, CPT1A, and N-Cadherin in tumor sections, and enhanced the inhibitory effect of TAM on these molecules in mice bearing MCF7/TR tumors (Fig. 9D and E).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Furthermore, IF staining identified that SLC31A1 depletion induced higher Caspase-3 cleavage levels in tumor tissues, which were further enhanced in these mice receiving TAM plus shSLC31A1 (Fig. 9F).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Taken together, we concluded that SLC31A1 upregulation enhanced copper transportation into breast cancer cells, which drove CPT1A expression, followed by FAO elevation, thereby facilitating the proliferation, EMT process, and TAM resistance, and suppressing apoptosis in ER-positive breast cancer cells (Fig. 9G).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "In summary, our findings uncovered that SLC31A1/copper axis was a significant drug-resistant factor, which could promote the proliferation, EMT and chemoresistance but restrain apoptosis in ER-positive breast cancer through promoting the expression of CPT1A and associated FAO process (Fig. 9G).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Among these DEGs, SLC31A1, a copper transporter, was highly expressed in the recurrent tumor specimens (Fig. 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Meanwhile, a gradually increasing SLC31A1 was detected in advanced-stage tumor specimens compared to those in the early stage (Fig. 1B and C).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "To further explore the prognostic value and expression of SLC31A1, the TCGA database was analyzed, and the result demonstrated that SLC31A1 expression was significantly upregulated in breast invasive carcinoma (BRCA) samples compared to the paired normal samples (Fig. 1D).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Additionally, higher SLC31A1 expression levels predicted poorer overall survival and progress-free interval survival rates than patients with lower SLC31A1 expression levels (Fig. 1E and F).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel E",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The results in Fig. 1G showed that SLC31A1 expression was significantly up-regulated in breast tumor tissues with ≥25-75% stained cells, while its corresponding normal tissues were moderately stained or unstained.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel G",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Data were presented as means ± SD. ⁎⁎P<0.01, ⁎⁎⁎P<0.001, ⁎⁎⁎⁎P<0.0001.SLC31A1 expression levels are up-regulated in ER-positive breast cancer patients\nIn this part, we verified higher expression of SLC31A1 in BRCA tissues compared to normal tissues through TIMER analysis (Fig. 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Despite detecting a positive correlation between SLC31A1 and ERBB2 (HER2) in BRCA samples, there was no significant difference observed between SLC31A1 and HER2 in BRCA-Basal and -Her2 specimens (Fig. 2B-E).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Additionally, no significant difference was detected between SLC31A1 expression and PGR expression in BRCA-Basal and BRCA samples (Fig. 2B and C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In vitro studies further demonstrated that SLCA31A mRNA and protein expression levels were higher in ER-positive breast cancer cell lines (T47D, MCF7, BT474, ZR-75-1), while being undetectable or slightly expressed in ER-negative breast cancer cell lines (MB231, HCC1954, MB453) and the normal epithelial cell line (MCF10A) (Fig. 2F-H).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "RT-qPCR results demonstrated that SLC31A1 was highly expressed in ER-positive breast cancer specimens in comparison to the matched adjacent normal tissues (Fig. 3A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Notably, much stronger SLC31A1 gene expression levels were detected in ER-positive breast cancer samples from patients with recurrence (R) than those of the patients without recurrence (NR) (Fig. 3C).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The IHC results revealed significantly stronger SLC31A1 protein expression levels in tumor sections collected from ER-positive breast cancer tissues with recurrence compared to the non-recurrent samples (Fig. 3D).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The IF staining analysis indicated that post-treatment tumors from the NR group exhibited similar SLC31A1 expression levels to their pre-treatment counterparts (Fig. 3E and F).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel E",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, post-treatment tumors from non-responders with recurrence showed a marked increase in SLC31A1 expression levels compared to their pre-treatment counterparts (Fig. 3G and H).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel G",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "IF staining results indicated that SLC31A1 expression was highly elevated in metastatic tissues compared to the primary tumor tissues (Fig. 3I and J).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel I",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Data were presented as means ± SD. ⁎⁎⁎P<0.001, ⁎⁎⁎⁎P<0.0001; ns, no significant difference.SLC31A1 deficiency rescues chemosensitivity in ER-positive breast cancer cells\nSubsequently, in vitro experiments were carried out to further investigate the impact of SLC31A1 expression changes on breast cancer progression and the underlying mechanisms using the TAM-sensitive breast cancer cell lines T47D and MCF7, and the constructed TAM-resistant (TR) ER-positive breast cancer cell lines (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Initially, RT-qPCR results indicated that T47D/TR and MCF7/TR cells exhibited significantly elevated expression of SLC31A1 at the mRNA level compared to the corresponding sensitive groups (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Western blot and IF staining confirmed significantly stronger SLC31A1 protein expression levels in T47D/TR and MCF7/TR cells than in the chemosensitive cell lines (Fig. 4C and D, Supplementary Fig. 1A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "RT-qPCR and western blot results confirmed the successful knockdown of SLC31A1 in breast cancer cells (Fig. 4E and F).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "More importantly, shSLC31A1 significantly enhanced the sensitivity of T47D/TR and MCF7/TR cells to TAM treatment, as indicated by the decreased cell viability through CCK-8 analysis (Fig. 4G).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Similarly, EdU staining confirmed that SLC31A1 depletion significantly reduced the proliferative capacity of T47D/TR and MCF7/TR cells in response to TAM incubation, which was comparable to the TAM single-treatment group (Fig. 4H).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel H",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel H",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel H",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Transwell analysis demonstrated that TAM had no significant effect on the invasion of T47D/TR and MCF7/TR cells, while shSLC31A1 infection strongly inhibited the invasive ability of TAM-resistant breast cancer cells (Fig. 4I), accompanied by a marked decrease in the expression of invasive markers, including N-Cadherin, VEFG, and matrix metalloproteinase-9 (MMP9) (Supplementary Fig. 2A-C).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel I",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel I",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel I",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Data were presented as means ± SD. ⁎⁎⁎P<0.001, ⁎⁎⁎⁎P<0.0001; +++P<0.001, ++++P<0.0001 vs the TAM group; ns, no significant difference.SLC31A1 promotes the proliferation and invasion of ER-positive breast cancer cells in vitro\nTo further confirm the association between SLC31A1 and TAM resistance in ER-positive breast cancer cells, we overexpressed SLC31A1 in parental T47D and MCF7 cells, which were identified by RT-qPCR and western blot assays (Fig. 5A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As anticipated, CCK-8 analysis indicated that SLC31A1 overexpression significantly restored the proliferation of T47D and MCF7 cells compared with the oe-Vec control group (Fig. 5C).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Notably, the TAM-restricted proliferation of T47D and MCF7 cells was notably abolished upon SLC31A1 overexpression (Fig. 5D).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Similarly, oe-SLC31A1 not only strongly promoted the invasion of T47D and MCF7 cells but also rescued the invasive ability of breast cancer cells (Fig. 5E), as evidenced by the increased number of invaded cells.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Consistent with this, the suppressed expression levels of N-Cadherin, VEGF, and MMP9 in T47D and MCF7 cells by TAM were significantly reduced when SLC31A1 was overexpressed (Fig. 5F).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As shown in Fig. 6A, we found higher copper concentrations in T47D/TR and MCF7/TR cells than that of their parental cell lines.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "We discovered that 481 genes were downregulated in T47D/TR cells relative to the control ones, encompassing CPT1A (Fig. 6B), a crucial gene in mediating the FAO process [29].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Further functional enrichment analysis of these DEGs by KEGG indicated that these signals were primarily implicated in the PPAR signaling pathway, fatty acid metabolism, gap junction, endocrine resistance, and fatty acid degradation (Fig. 6C).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "GSEA based on the acquired DEGs consistently disclosed that SLC31A1 was affiliated with fatty acid β-oxidation and metabolism (Fig. 6D).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "RT-qPCR results further demonstrated that the deletion of SLC31A1 conspicuously alleviated the expression of genes specifically implicated in FAO, including CPT1A, CPT1B, ACOX1, and 3-hydroxymethylglutaryl-CoA synthase 2 (HMGCS2), but augmented the fatty acid synthesis-related genes fatty acid synthase (FASN), acetyl-CoA carboxylase (ACC), and stearoyl-CoA desaturase (SCD) (Fig. 6E).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel E",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel E",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel E",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "RT-qPCR and western blot assays indicated that T47D/TR and MCF7/TR cells manifested stronger CPT1A mRNA and protein expression levels than those of the parental breast cancer cell lines (Fig. 6F and G).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel F",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "As anticipated, higher FAO and ATP levels were detected in T47D/TR and MCF7/TR compared to the chemosensitive breast cancer cell lines (Fig. 6H and I).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel H",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Notably, CPT1A deficiency significantly enhanced the chemosensitivity of T47D/TR and MCF7/TR cells to TAM incubation by CCK-8 analysis (Fig. 6J).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel J",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel J",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel J",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "In accordance with expectation, CPT1A deletion resulted in significantly higher lipid deposition in TAM-resistant T47D and MCF7 cells (Fig. 6K), as indicated by the larger size of lipid droplets, revealing the limited FAO process.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel K",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel K",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel K",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Furthermore, PO-induced mitochondrial injury was exacerbated in T47D/TR and MCF7/TR cells transfected with siCPT1A (Fig. 6L).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel L",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel L",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel L",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Together, these results above demonstrated that SLC31A1-mediated recurrence of ER-positive breast cancer might be associated with FAO process through controlling CPT1A expression.Copper/SLC31A1 enhances CPT1A expression levels in chemoresistant breast cancer cells\nTo explore the physiological effects of copper on CPT1A expression in TAM-resistant breast cancer cells, we discovered that copper supplementation led to CPT1A expression levels in a dose-dependent manner, and importantly, SLC31A1 deletion could significantly abrogate copper-triggered increase of CPT1A in T47D/TR and MCF7/TR cell lines (Fig. 7A).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Moreover, CPT1A suppression by its specific inhibitor ETO or siCPT1A markedly mitigated CPT1A expression levels in T47D/TR and MCF7/TR cells under copper exposure (Fig. 7B).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Subsequently, we found that copper-induced CPT1A up-regulation was potently antagonized by copper chelator TTM in chemoresistant breast cancer cell lines (Fig. 7C).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "As expected, promoting SLC31A1 expression significantly enhanced CPT1A in T47D and MCF7 cells (Fig. 8A), along with higher copper concentrations (Fig. 8B).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Moreover, FAO rates and ATP levels were markedly upregulated by SLC31A1 overexpression in parental breast cancer cells (Fig. 8C and D).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel C",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Surprisingly, CCK8-analysis revealed that SLC31A1-facilitated proliferation of T47D and MCF7 cells was significantly abolished when CPT1A expression was inhibited by siCPT1A and ETO (Fig. 8E), which was validated by EdU staining (Fig. 8F and G), evidenced by the strongly decreased EdU-positive cells.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel E",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel F",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel E",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel E",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Transwell analysis further demonstrated that CPT1A expression suppression abolished the promotive effect of SLC31A1 on the invasion of breast cancer cells (Fig. 8H and I).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel H",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "In addition, in T47D and MCF7 cells overexpressing SLC31A1, CPT1A inhibition significantly reduced the FAO rates and ATP levels (Fig. 8J and K), along with diminished expression levels of CPT1A (Fig. 8L).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel J",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel L",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel L",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel L",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "As shown in Fig. 9A-C, TAM treatment had no significant effect on tumor growth compared to the control group; however, stable SLC31A1 knockdown not only significantly reduced the tumor growth rates and tumor weight, but also enhanced the response of these mice to TAM treatment, as indicated by the much lower tumor volume and weight.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "H&E staining indicated that the tumor cell density was significantly reduced in mice receiving TAM and shSLC31A1 combinatorial treatments (Fig. 9D).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "IHC staining further demonstrated that SLC31A1 deletion markedly decreased the positive expression of KI-67, CPT1A, and N-Cadherin in tumor sections, and enhanced the inhibitory effect of TAM on these molecules in mice bearing MCF7/TR tumors (Fig. 9D and E).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Furthermore, IF staining identified that SLC31A1 depletion induced higher Caspase-3 cleavage levels in tumor tissues, which were further enhanced in these mice receiving TAM plus shSLC31A1 (Fig. 9F).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Taken together, we concluded that SLC31A1 upregulation enhanced copper transportation into breast cancer cells, which drove CPT1A expression, followed by FAO elevation, thereby facilitating the proliferation, EMT process, and TAM resistance, and suppressing apoptosis in ER-positive breast cancer cells (Fig. 9G).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "In summary, our findings uncovered that SLC31A1/copper axis was a significant drug-resistant factor, which could promote the proliferation, EMT and chemoresistance but restrain apoptosis in ER-positive breast cancer through promoting the expression of CPT1A and associated FAO process (Fig. 9G).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Among these DEGs, SLC31A1, a copper transporter, was highly expressed in the recurrent tumor specimens (Fig. 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Meanwhile, a gradually increasing SLC31A1 was detected in advanced-stage tumor specimens compared to those in the early stage (Fig. 1B and C).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "To further explore the prognostic value and expression of SLC31A1, the TCGA database was analyzed, and the result demonstrated that SLC31A1 expression was significantly upregulated in breast invasive carcinoma (BRCA) samples compared to the paired normal samples (Fig. 1D).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Additionally, higher SLC31A1 expression levels predicted poorer overall survival and progress-free interval survival rates than patients with lower SLC31A1 expression levels (Fig. 1E and F).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel E",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The results in Fig. 1G showed that SLC31A1 expression was significantly up-regulated in breast tumor tissues with ≥25-75% stained cells, while its corresponding normal tissues were moderately stained or unstained.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel G",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Data were presented as means ± SD. ⁎⁎P<0.01, ⁎⁎⁎P<0.001, ⁎⁎⁎⁎P<0.0001.SLC31A1 expression levels are up-regulated in ER-positive breast cancer patients\nIn this part, we verified higher expression of SLC31A1 in BRCA tissues compared to normal tissues through TIMER analysis (Fig. 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Despite detecting a positive correlation between SLC31A1 and ERBB2 (HER2) in BRCA samples, there was no significant difference observed between SLC31A1 and HER2 in BRCA-Basal and -Her2 specimens (Fig. 2B-E).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Additionally, no significant difference was detected between SLC31A1 expression and PGR expression in BRCA-Basal and BRCA samples (Fig. 2B and C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In vitro studies further demonstrated that SLCA31A mRNA and protein expression levels were higher in ER-positive breast cancer cell lines (T47D, MCF7, BT474, ZR-75-1), while being undetectable or slightly expressed in ER-negative breast cancer cell lines (MB231, HCC1954, MB453) and the normal epithelial cell line (MCF10A) (Fig. 2F-H).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "RT-qPCR results demonstrated that SLC31A1 was highly expressed in ER-positive breast cancer specimens in comparison to the matched adjacent normal tissues (Fig. 3A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Notably, much stronger SLC31A1 gene expression levels were detected in ER-positive breast cancer samples from patients with recurrence (R) than those of the patients without recurrence (NR) (Fig. 3C).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The IHC results revealed significantly stronger SLC31A1 protein expression levels in tumor sections collected from ER-positive breast cancer tissues with recurrence compared to the non-recurrent samples (Fig. 3D).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The IF staining analysis indicated that post-treatment tumors from the NR group exhibited similar SLC31A1 expression levels to their pre-treatment counterparts (Fig. 3E and F).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel E",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, post-treatment tumors from non-responders with recurrence showed a marked increase in SLC31A1 expression levels compared to their pre-treatment counterparts (Fig. 3G and H).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel G",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "IF staining results indicated that SLC31A1 expression was highly elevated in metastatic tissues compared to the primary tumor tissues (Fig. 3I and J).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel I",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Data were presented as means ± SD. ⁎⁎⁎P<0.001, ⁎⁎⁎⁎P<0.0001; ns, no significant difference.SLC31A1 deficiency rescues chemosensitivity in ER-positive breast cancer cells\nSubsequently, in vitro experiments were carried out to further investigate the impact of SLC31A1 expression changes on breast cancer progression and the underlying mechanisms using the TAM-sensitive breast cancer cell lines T47D and MCF7, and the constructed TAM-resistant (TR) ER-positive breast cancer cell lines (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Initially, RT-qPCR results indicated that T47D/TR and MCF7/TR cells exhibited significantly elevated expression of SLC31A1 at the mRNA level compared to the corresponding sensitive groups (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Western blot and IF staining confirmed significantly stronger SLC31A1 protein expression levels in T47D/TR and MCF7/TR cells than in the chemosensitive cell lines (Fig. 4C and D, Supplementary Fig. 1A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "RT-qPCR and western blot results confirmed the successful knockdown of SLC31A1 in breast cancer cells (Fig. 4E and F).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "More importantly, shSLC31A1 significantly enhanced the sensitivity of T47D/TR and MCF7/TR cells to TAM treatment, as indicated by the decreased cell viability through CCK-8 analysis (Fig. 4G).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Similarly, EdU staining confirmed that SLC31A1 depletion significantly reduced the proliferative capacity of T47D/TR and MCF7/TR cells in response to TAM incubation, which was comparable to the TAM single-treatment group (Fig. 4H).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel H",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel H",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel H",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Transwell analysis demonstrated that TAM had no significant effect on the invasion of T47D/TR and MCF7/TR cells, while shSLC31A1 infection strongly inhibited the invasive ability of TAM-resistant breast cancer cells (Fig. 4I), accompanied by a marked decrease in the expression of invasive markers, including N-Cadherin, VEFG, and matrix metalloproteinase-9 (MMP9) (Supplementary Fig. 2A-C).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel I",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel I",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel I",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Data were presented as means ± SD. ⁎⁎⁎P<0.001, ⁎⁎⁎⁎P<0.0001; +++P<0.001, ++++P<0.0001 vs the TAM group; ns, no significant difference.SLC31A1 promotes the proliferation and invasion of ER-positive breast cancer cells in vitro\nTo further confirm the association between SLC31A1 and TAM resistance in ER-positive breast cancer cells, we overexpressed SLC31A1 in parental T47D and MCF7 cells, which were identified by RT-qPCR and western blot assays (Fig. 5A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As anticipated, CCK-8 analysis indicated that SLC31A1 overexpression significantly restored the proliferation of T47D and MCF7 cells compared with the oe-Vec control group (Fig. 5C).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Notably, the TAM-restricted proliferation of T47D and MCF7 cells was notably abolished upon SLC31A1 overexpression (Fig. 5D).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Similarly, oe-SLC31A1 not only strongly promoted the invasion of T47D and MCF7 cells but also rescued the invasive ability of breast cancer cells (Fig. 5E), as evidenced by the increased number of invaded cells.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Consistent with this, the suppressed expression levels of N-Cadherin, VEGF, and MMP9 in T47D and MCF7 cells by TAM were significantly reduced when SLC31A1 was overexpressed (Fig. 5F).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As shown in Fig. 6A, we found higher copper concentrations in T47D/TR and MCF7/TR cells than that of their parental cell lines.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "We discovered that 481 genes were downregulated in T47D/TR cells relative to the control ones, encompassing CPT1A (Fig. 6B), a crucial gene in mediating the FAO process [29].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Further functional enrichment analysis of these DEGs by KEGG indicated that these signals were primarily implicated in the PPAR signaling pathway, fatty acid metabolism, gap junction, endocrine resistance, and fatty acid degradation (Fig. 6C).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "GSEA based on the acquired DEGs consistently disclosed that SLC31A1 was affiliated with fatty acid β-oxidation and metabolism (Fig. 6D).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "RT-qPCR results further demonstrated that the deletion of SLC31A1 conspicuously alleviated the expression of genes specifically implicated in FAO, including CPT1A, CPT1B, ACOX1, and 3-hydroxymethylglutaryl-CoA synthase 2 (HMGCS2), but augmented the fatty acid synthesis-related genes fatty acid synthase (FASN), acetyl-CoA carboxylase (ACC), and stearoyl-CoA desaturase (SCD) (Fig. 6E).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel E",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel E",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel E",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "RT-qPCR and western blot assays indicated that T47D/TR and MCF7/TR cells manifested stronger CPT1A mRNA and protein expression levels than those of the parental breast cancer cell lines (Fig. 6F and G).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel F",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "As anticipated, higher FAO and ATP levels were detected in T47D/TR and MCF7/TR compared to the chemosensitive breast cancer cell lines (Fig. 6H and I).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel H",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Notably, CPT1A deficiency significantly enhanced the chemosensitivity of T47D/TR and MCF7/TR cells to TAM incubation by CCK-8 analysis (Fig. 6J).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel J",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel J",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel J",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "In accordance with expectation, CPT1A deletion resulted in significantly higher lipid deposition in TAM-resistant T47D and MCF7 cells (Fig. 6K), as indicated by the larger size of lipid droplets, revealing the limited FAO process.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel K",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel K",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel K",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Furthermore, PO-induced mitochondrial injury was exacerbated in T47D/TR and MCF7/TR cells transfected with siCPT1A (Fig. 6L).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel L",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel L",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel L",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Together, these results above demonstrated that SLC31A1-mediated recurrence of ER-positive breast cancer might be associated with FAO process through controlling CPT1A expression.Copper/SLC31A1 enhances CPT1A expression levels in chemoresistant breast cancer cells\nTo explore the physiological effects of copper on CPT1A expression in TAM-resistant breast cancer cells, we discovered that copper supplementation led to CPT1A expression levels in a dose-dependent manner, and importantly, SLC31A1 deletion could significantly abrogate copper-triggered increase of CPT1A in T47D/TR and MCF7/TR cell lines (Fig. 7A).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Moreover, CPT1A suppression by its specific inhibitor ETO or siCPT1A markedly mitigated CPT1A expression levels in T47D/TR and MCF7/TR cells under copper exposure (Fig. 7B).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Subsequently, we found that copper-induced CPT1A up-regulation was potently antagonized by copper chelator TTM in chemoresistant breast cancer cell lines (Fig. 7C).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "As expected, promoting SLC31A1 expression significantly enhanced CPT1A in T47D and MCF7 cells (Fig. 8A), along with higher copper concentrations (Fig. 8B).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Moreover, FAO rates and ATP levels were markedly upregulated by SLC31A1 overexpression in parental breast cancer cells (Fig. 8C and D).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel C",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Surprisingly, CCK8-analysis revealed that SLC31A1-facilitated proliferation of T47D and MCF7 cells was significantly abolished when CPT1A expression was inhibited by siCPT1A and ETO (Fig. 8E), which was validated by EdU staining (Fig. 8F and G), evidenced by the strongly decreased EdU-positive cells.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel E",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel F",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel E",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel E",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Transwell analysis further demonstrated that CPT1A expression suppression abolished the promotive effect of SLC31A1 on the invasion of breast cancer cells (Fig. 8H and I).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel H",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "In addition, in T47D and MCF7 cells overexpressing SLC31A1, CPT1A inhibition significantly reduced the FAO rates and ATP levels (Fig. 8J and K), along with diminished expression levels of CPT1A (Fig. 8L).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel J",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel L",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel L",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel L",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "As shown in Fig. 9A-C, TAM treatment had no significant effect on tumor growth compared to the control group; however, stable SLC31A1 knockdown not only significantly reduced the tumor growth rates and tumor weight, but also enhanced the response of these mice to TAM treatment, as indicated by the much lower tumor volume and weight.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "H&E staining indicated that the tumor cell density was significantly reduced in mice receiving TAM and shSLC31A1 combinatorial treatments (Fig. 9D).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "IHC staining further demonstrated that SLC31A1 deletion markedly decreased the positive expression of KI-67, CPT1A, and N-Cadherin in tumor sections, and enhanced the inhibitory effect of TAM on these molecules in mice bearing MCF7/TR tumors (Fig. 9D and E).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Furthermore, IF staining identified that SLC31A1 depletion induced higher Caspase-3 cleavage levels in tumor tissues, which were further enhanced in these mice receiving TAM plus shSLC31A1 (Fig. 9F).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Taken together, we concluded that SLC31A1 upregulation enhanced copper transportation into breast cancer cells, which drove CPT1A expression, followed by FAO elevation, thereby facilitating the proliferation, EMT process, and TAM resistance, and suppressing apoptosis in ER-positive breast cancer cells (Fig. 9G).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "In summary, our findings uncovered that SLC31A1/copper axis was a significant drug-resistant factor, which could promote the proliferation, EMT and chemoresistance but restrain apoptosis in ER-positive breast cancer through promoting the expression of CPT1A and associated FAO process (Fig. 9G).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Among these DEGs, SLC31A1, a copper transporter, was highly expressed in the recurrent tumor specimens (Fig. 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Meanwhile, a gradually increasing SLC31A1 was detected in advanced-stage tumor specimens compared to those in the early stage (Fig. 1B and C).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "To further explore the prognostic value and expression of SLC31A1, the TCGA database was analyzed, and the result demonstrated that SLC31A1 expression was significantly upregulated in breast invasive carcinoma (BRCA) samples compared to the paired normal samples (Fig. 1D).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Additionally, higher SLC31A1 expression levels predicted poorer overall survival and progress-free interval survival rates than patients with lower SLC31A1 expression levels (Fig. 1E and F).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel E",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The results in Fig. 1G showed that SLC31A1 expression was significantly up-regulated in breast tumor tissues with ≥25-75% stained cells, while its corresponding normal tissues were moderately stained or unstained.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel G",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Data were presented as means ± SD. ⁎⁎P<0.01, ⁎⁎⁎P<0.001, ⁎⁎⁎⁎P<0.0001.SLC31A1 expression levels are up-regulated in ER-positive breast cancer patients\nIn this part, we verified higher expression of SLC31A1 in BRCA tissues compared to normal tissues through TIMER analysis (Fig. 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Despite detecting a positive correlation between SLC31A1 and ERBB2 (HER2) in BRCA samples, there was no significant difference observed between SLC31A1 and HER2 in BRCA-Basal and -Her2 specimens (Fig. 2B-E).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Additionally, no significant difference was detected between SLC31A1 expression and PGR expression in BRCA-Basal and BRCA samples (Fig. 2B and C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In vitro studies further demonstrated that SLCA31A mRNA and protein expression levels were higher in ER-positive breast cancer cell lines (T47D, MCF7, BT474, ZR-75-1), while being undetectable or slightly expressed in ER-negative breast cancer cell lines (MB231, HCC1954, MB453) and the normal epithelial cell line (MCF10A) (Fig. 2F-H).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "RT-qPCR results demonstrated that SLC31A1 was highly expressed in ER-positive breast cancer specimens in comparison to the matched adjacent normal tissues (Fig. 3A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Notably, much stronger SLC31A1 gene expression levels were detected in ER-positive breast cancer samples from patients with recurrence (R) than those of the patients without recurrence (NR) (Fig. 3C).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The IHC results revealed significantly stronger SLC31A1 protein expression levels in tumor sections collected from ER-positive breast cancer tissues with recurrence compared to the non-recurrent samples (Fig. 3D).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The IF staining analysis indicated that post-treatment tumors from the NR group exhibited similar SLC31A1 expression levels to their pre-treatment counterparts (Fig. 3E and F).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel E",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, post-treatment tumors from non-responders with recurrence showed a marked increase in SLC31A1 expression levels compared to their pre-treatment counterparts (Fig. 3G and H).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel G",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "IF staining results indicated that SLC31A1 expression was highly elevated in metastatic tissues compared to the primary tumor tissues (Fig. 3I and J).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel I",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Data were presented as means ± SD. ⁎⁎⁎P<0.001, ⁎⁎⁎⁎P<0.0001; ns, no significant difference.SLC31A1 deficiency rescues chemosensitivity in ER-positive breast cancer cells\nSubsequently, in vitro experiments were carried out to further investigate the impact of SLC31A1 expression changes on breast cancer progression and the underlying mechanisms using the TAM-sensitive breast cancer cell lines T47D and MCF7, and the constructed TAM-resistant (TR) ER-positive breast cancer cell lines (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Initially, RT-qPCR results indicated that T47D/TR and MCF7/TR cells exhibited significantly elevated expression of SLC31A1 at the mRNA level compared to the corresponding sensitive groups (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Western blot and IF staining confirmed significantly stronger SLC31A1 protein expression levels in T47D/TR and MCF7/TR cells than in the chemosensitive cell lines (Fig. 4C and D, Supplementary Fig. 1A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "RT-qPCR and western blot results confirmed the successful knockdown of SLC31A1 in breast cancer cells (Fig. 4E and F).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "More importantly, shSLC31A1 significantly enhanced the sensitivity of T47D/TR and MCF7/TR cells to TAM treatment, as indicated by the decreased cell viability through CCK-8 analysis (Fig. 4G).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Similarly, EdU staining confirmed that SLC31A1 depletion significantly reduced the proliferative capacity of T47D/TR and MCF7/TR cells in response to TAM incubation, which was comparable to the TAM single-treatment group (Fig. 4H).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel H",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel H",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel H",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Transwell analysis demonstrated that TAM had no significant effect on the invasion of T47D/TR and MCF7/TR cells, while shSLC31A1 infection strongly inhibited the invasive ability of TAM-resistant breast cancer cells (Fig. 4I), accompanied by a marked decrease in the expression of invasive markers, including N-Cadherin, VEFG, and matrix metalloproteinase-9 (MMP9) (Supplementary Fig. 2A-C).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel I",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel I",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel I",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Data were presented as means ± SD. ⁎⁎⁎P<0.001, ⁎⁎⁎⁎P<0.0001; +++P<0.001, ++++P<0.0001 vs the TAM group; ns, no significant difference.SLC31A1 promotes the proliferation and invasion of ER-positive breast cancer cells in vitro\nTo further confirm the association between SLC31A1 and TAM resistance in ER-positive breast cancer cells, we overexpressed SLC31A1 in parental T47D and MCF7 cells, which were identified by RT-qPCR and western blot assays (Fig. 5A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As anticipated, CCK-8 analysis indicated that SLC31A1 overexpression significantly restored the proliferation of T47D and MCF7 cells compared with the oe-Vec control group (Fig. 5C).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Notably, the TAM-restricted proliferation of T47D and MCF7 cells was notably abolished upon SLC31A1 overexpression (Fig. 5D).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Similarly, oe-SLC31A1 not only strongly promoted the invasion of T47D and MCF7 cells but also rescued the invasive ability of breast cancer cells (Fig. 5E), as evidenced by the increased number of invaded cells.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Consistent with this, the suppressed expression levels of N-Cadherin, VEGF, and MMP9 in T47D and MCF7 cells by TAM were significantly reduced when SLC31A1 was overexpressed (Fig. 5F).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As shown in Fig. 6A, we found higher copper concentrations in T47D/TR and MCF7/TR cells than that of their parental cell lines.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "We discovered that 481 genes were downregulated in T47D/TR cells relative to the control ones, encompassing CPT1A (Fig. 6B), a crucial gene in mediating the FAO process [29].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Further functional enrichment analysis of these DEGs by KEGG indicated that these signals were primarily implicated in the PPAR signaling pathway, fatty acid metabolism, gap junction, endocrine resistance, and fatty acid degradation (Fig. 6C).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "GSEA based on the acquired DEGs consistently disclosed that SLC31A1 was affiliated with fatty acid β-oxidation and metabolism (Fig. 6D).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "RT-qPCR results further demonstrated that the deletion of SLC31A1 conspicuously alleviated the expression of genes specifically implicated in FAO, including CPT1A, CPT1B, ACOX1, and 3-hydroxymethylglutaryl-CoA synthase 2 (HMGCS2), but augmented the fatty acid synthesis-related genes fatty acid synthase (FASN), acetyl-CoA carboxylase (ACC), and stearoyl-CoA desaturase (SCD) (Fig. 6E).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel E",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel E",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel E",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "RT-qPCR and western blot assays indicated that T47D/TR and MCF7/TR cells manifested stronger CPT1A mRNA and protein expression levels than those of the parental breast cancer cell lines (Fig. 6F and G).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel F",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "As anticipated, higher FAO and ATP levels were detected in T47D/TR and MCF7/TR compared to the chemosensitive breast cancer cell lines (Fig. 6H and I).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel H",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Notably, CPT1A deficiency significantly enhanced the chemosensitivity of T47D/TR and MCF7/TR cells to TAM incubation by CCK-8 analysis (Fig. 6J).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel J",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel J",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel J",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "In accordance with expectation, CPT1A deletion resulted in significantly higher lipid deposition in TAM-resistant T47D and MCF7 cells (Fig. 6K), as indicated by the larger size of lipid droplets, revealing the limited FAO process.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel K",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel K",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel K",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Furthermore, PO-induced mitochondrial injury was exacerbated in T47D/TR and MCF7/TR cells transfected with siCPT1A (Fig. 6L).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel L",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel L",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel L",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Together, these results above demonstrated that SLC31A1-mediated recurrence of ER-positive breast cancer might be associated with FAO process through controlling CPT1A expression.Copper/SLC31A1 enhances CPT1A expression levels in chemoresistant breast cancer cells\nTo explore the physiological effects of copper on CPT1A expression in TAM-resistant breast cancer cells, we discovered that copper supplementation led to CPT1A expression levels in a dose-dependent manner, and importantly, SLC31A1 deletion could significantly abrogate copper-triggered increase of CPT1A in T47D/TR and MCF7/TR cell lines (Fig. 7A).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Moreover, CPT1A suppression by its specific inhibitor ETO or siCPT1A markedly mitigated CPT1A expression levels in T47D/TR and MCF7/TR cells under copper exposure (Fig. 7B).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Subsequently, we found that copper-induced CPT1A up-regulation was potently antagonized by copper chelator TTM in chemoresistant breast cancer cell lines (Fig. 7C).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "As expected, promoting SLC31A1 expression significantly enhanced CPT1A in T47D and MCF7 cells (Fig. 8A), along with higher copper concentrations (Fig. 8B).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Moreover, FAO rates and ATP levels were markedly upregulated by SLC31A1 overexpression in parental breast cancer cells (Fig. 8C and D).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel C",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Surprisingly, CCK8-analysis revealed that SLC31A1-facilitated proliferation of T47D and MCF7 cells was significantly abolished when CPT1A expression was inhibited by siCPT1A and ETO (Fig. 8E), which was validated by EdU staining (Fig. 8F and G), evidenced by the strongly decreased EdU-positive cells.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel E",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel F",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel E",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel E",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Transwell analysis further demonstrated that CPT1A expression suppression abolished the promotive effect of SLC31A1 on the invasion of breast cancer cells (Fig. 8H and I).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel H",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "In addition, in T47D and MCF7 cells overexpressing SLC31A1, CPT1A inhibition significantly reduced the FAO rates and ATP levels (Fig. 8J and K), along with diminished expression levels of CPT1A (Fig. 8L).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel J",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel L",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel L",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel L",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "As shown in Fig. 9A-C, TAM treatment had no significant effect on tumor growth compared to the control group; however, stable SLC31A1 knockdown not only significantly reduced the tumor growth rates and tumor weight, but also enhanced the response of these mice to TAM treatment, as indicated by the much lower tumor volume and weight.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "H&E staining indicated that the tumor cell density was significantly reduced in mice receiving TAM and shSLC31A1 combinatorial treatments (Fig. 9D).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "IHC staining further demonstrated that SLC31A1 deletion markedly decreased the positive expression of KI-67, CPT1A, and N-Cadherin in tumor sections, and enhanced the inhibitory effect of TAM on these molecules in mice bearing MCF7/TR tumors (Fig. 9D and E).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Furthermore, IF staining identified that SLC31A1 depletion induced higher Caspase-3 cleavage levels in tumor tissues, which were further enhanced in these mice receiving TAM plus shSLC31A1 (Fig. 9F).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Taken together, we concluded that SLC31A1 upregulation enhanced copper transportation into breast cancer cells, which drove CPT1A expression, followed by FAO elevation, thereby facilitating the proliferation, EMT process, and TAM resistance, and suppressing apoptosis in ER-positive breast cancer cells (Fig. 9G).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "In summary, our findings uncovered that SLC31A1/copper axis was a significant drug-resistant factor, which could promote the proliferation, EMT and chemoresistance but restrain apoptosis in ER-positive breast cancer through promoting the expression of CPT1A and associated FAO process (Fig. 9G).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Among these DEGs, SLC31A1, a copper transporter, was highly expressed in the recurrent tumor specimens (Fig. 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Meanwhile, a gradually increasing SLC31A1 was detected in advanced-stage tumor specimens compared to those in the early stage (Fig. 1B and C).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "To further explore the prognostic value and expression of SLC31A1, the TCGA database was analyzed, and the result demonstrated that SLC31A1 expression was significantly upregulated in breast invasive carcinoma (BRCA) samples compared to the paired normal samples (Fig. 1D).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Additionally, higher SLC31A1 expression levels predicted poorer overall survival and progress-free interval survival rates than patients with lower SLC31A1 expression levels (Fig. 1E and F).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel E",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The results in Fig. 1G showed that SLC31A1 expression was significantly up-regulated in breast tumor tissues with ≥25-75% stained cells, while its corresponding normal tissues were moderately stained or unstained.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel G",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Data were presented as means ± SD. ⁎⁎P<0.01, ⁎⁎⁎P<0.001, ⁎⁎⁎⁎P<0.0001.SLC31A1 expression levels are up-regulated in ER-positive breast cancer patients\nIn this part, we verified higher expression of SLC31A1 in BRCA tissues compared to normal tissues through TIMER analysis (Fig. 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Despite detecting a positive correlation between SLC31A1 and ERBB2 (HER2) in BRCA samples, there was no significant difference observed between SLC31A1 and HER2 in BRCA-Basal and -Her2 specimens (Fig. 2B-E).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Additionally, no significant difference was detected between SLC31A1 expression and PGR expression in BRCA-Basal and BRCA samples (Fig. 2B and C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In vitro studies further demonstrated that SLCA31A mRNA and protein expression levels were higher in ER-positive breast cancer cell lines (T47D, MCF7, BT474, ZR-75-1), while being undetectable or slightly expressed in ER-negative breast cancer cell lines (MB231, HCC1954, MB453) and the normal epithelial cell line (MCF10A) (Fig. 2F-H).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "RT-qPCR results demonstrated that SLC31A1 was highly expressed in ER-positive breast cancer specimens in comparison to the matched adjacent normal tissues (Fig. 3A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Notably, much stronger SLC31A1 gene expression levels were detected in ER-positive breast cancer samples from patients with recurrence (R) than those of the patients without recurrence (NR) (Fig. 3C).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The IHC results revealed significantly stronger SLC31A1 protein expression levels in tumor sections collected from ER-positive breast cancer tissues with recurrence compared to the non-recurrent samples (Fig. 3D).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The IF staining analysis indicated that post-treatment tumors from the NR group exhibited similar SLC31A1 expression levels to their pre-treatment counterparts (Fig. 3E and F).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel E",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, post-treatment tumors from non-responders with recurrence showed a marked increase in SLC31A1 expression levels compared to their pre-treatment counterparts (Fig. 3G and H).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel G",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "IF staining results indicated that SLC31A1 expression was highly elevated in metastatic tissues compared to the primary tumor tissues (Fig. 3I and J).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel I",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Data were presented as means ± SD. ⁎⁎⁎P<0.001, ⁎⁎⁎⁎P<0.0001; ns, no significant difference.SLC31A1 deficiency rescues chemosensitivity in ER-positive breast cancer cells\nSubsequently, in vitro experiments were carried out to further investigate the impact of SLC31A1 expression changes on breast cancer progression and the underlying mechanisms using the TAM-sensitive breast cancer cell lines T47D and MCF7, and the constructed TAM-resistant (TR) ER-positive breast cancer cell lines (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Initially, RT-qPCR results indicated that T47D/TR and MCF7/TR cells exhibited significantly elevated expression of SLC31A1 at the mRNA level compared to the corresponding sensitive groups (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Western blot and IF staining confirmed significantly stronger SLC31A1 protein expression levels in T47D/TR and MCF7/TR cells than in the chemosensitive cell lines (Fig. 4C and D, Supplementary Fig. 1A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "RT-qPCR and western blot results confirmed the successful knockdown of SLC31A1 in breast cancer cells (Fig. 4E and F).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "More importantly, shSLC31A1 significantly enhanced the sensitivity of T47D/TR and MCF7/TR cells to TAM treatment, as indicated by the decreased cell viability through CCK-8 analysis (Fig. 4G).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Similarly, EdU staining confirmed that SLC31A1 depletion significantly reduced the proliferative capacity of T47D/TR and MCF7/TR cells in response to TAM incubation, which was comparable to the TAM single-treatment group (Fig. 4H).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel H",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel H",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel H",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Transwell analysis demonstrated that TAM had no significant effect on the invasion of T47D/TR and MCF7/TR cells, while shSLC31A1 infection strongly inhibited the invasive ability of TAM-resistant breast cancer cells (Fig. 4I), accompanied by a marked decrease in the expression of invasive markers, including N-Cadherin, VEFG, and matrix metalloproteinase-9 (MMP9) (Supplementary Fig. 2A-C).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel I",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel I",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel I",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Data were presented as means ± SD. ⁎⁎⁎P<0.001, ⁎⁎⁎⁎P<0.0001; +++P<0.001, ++++P<0.0001 vs the TAM group; ns, no significant difference.SLC31A1 promotes the proliferation and invasion of ER-positive breast cancer cells in vitro\nTo further confirm the association between SLC31A1 and TAM resistance in ER-positive breast cancer cells, we overexpressed SLC31A1 in parental T47D and MCF7 cells, which were identified by RT-qPCR and western blot assays (Fig. 5A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As anticipated, CCK-8 analysis indicated that SLC31A1 overexpression significantly restored the proliferation of T47D and MCF7 cells compared with the oe-Vec control group (Fig. 5C).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Notably, the TAM-restricted proliferation of T47D and MCF7 cells was notably abolished upon SLC31A1 overexpression (Fig. 5D).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Similarly, oe-SLC31A1 not only strongly promoted the invasion of T47D and MCF7 cells but also rescued the invasive ability of breast cancer cells (Fig. 5E), as evidenced by the increased number of invaded cells.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Consistent with this, the suppressed expression levels of N-Cadherin, VEGF, and MMP9 in T47D and MCF7 cells by TAM were significantly reduced when SLC31A1 was overexpressed (Fig. 5F).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As shown in Fig. 6A, we found higher copper concentrations in T47D/TR and MCF7/TR cells than that of their parental cell lines.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "We discovered that 481 genes were downregulated in T47D/TR cells relative to the control ones, encompassing CPT1A (Fig. 6B), a crucial gene in mediating the FAO process [29].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Further functional enrichment analysis of these DEGs by KEGG indicated that these signals were primarily implicated in the PPAR signaling pathway, fatty acid metabolism, gap junction, endocrine resistance, and fatty acid degradation (Fig. 6C).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "GSEA based on the acquired DEGs consistently disclosed that SLC31A1 was affiliated with fatty acid β-oxidation and metabolism (Fig. 6D).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "RT-qPCR results further demonstrated that the deletion of SLC31A1 conspicuously alleviated the expression of genes specifically implicated in FAO, including CPT1A, CPT1B, ACOX1, and 3-hydroxymethylglutaryl-CoA synthase 2 (HMGCS2), but augmented the fatty acid synthesis-related genes fatty acid synthase (FASN), acetyl-CoA carboxylase (ACC), and stearoyl-CoA desaturase (SCD) (Fig. 6E).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel E",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel E",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel E",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "RT-qPCR and western blot assays indicated that T47D/TR and MCF7/TR cells manifested stronger CPT1A mRNA and protein expression levels than those of the parental breast cancer cell lines (Fig. 6F and G).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel F",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "As anticipated, higher FAO and ATP levels were detected in T47D/TR and MCF7/TR compared to the chemosensitive breast cancer cell lines (Fig. 6H and I).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel H",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Notably, CPT1A deficiency significantly enhanced the chemosensitivity of T47D/TR and MCF7/TR cells to TAM incubation by CCK-8 analysis (Fig. 6J).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel J",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel J",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel J",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "In accordance with expectation, CPT1A deletion resulted in significantly higher lipid deposition in TAM-resistant T47D and MCF7 cells (Fig. 6K), as indicated by the larger size of lipid droplets, revealing the limited FAO process.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel K",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel K",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel K",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Furthermore, PO-induced mitochondrial injury was exacerbated in T47D/TR and MCF7/TR cells transfected with siCPT1A (Fig. 6L).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel L",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel L",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel L",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Together, these results above demonstrated that SLC31A1-mediated recurrence of ER-positive breast cancer might be associated with FAO process through controlling CPT1A expression.Copper/SLC31A1 enhances CPT1A expression levels in chemoresistant breast cancer cells\nTo explore the physiological effects of copper on CPT1A expression in TAM-resistant breast cancer cells, we discovered that copper supplementation led to CPT1A expression levels in a dose-dependent manner, and importantly, SLC31A1 deletion could significantly abrogate copper-triggered increase of CPT1A in T47D/TR and MCF7/TR cell lines (Fig. 7A).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Moreover, CPT1A suppression by its specific inhibitor ETO or siCPT1A markedly mitigated CPT1A expression levels in T47D/TR and MCF7/TR cells under copper exposure (Fig. 7B).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Subsequently, we found that copper-induced CPT1A up-regulation was potently antagonized by copper chelator TTM in chemoresistant breast cancer cell lines (Fig. 7C).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "As expected, promoting SLC31A1 expression significantly enhanced CPT1A in T47D and MCF7 cells (Fig. 8A), along with higher copper concentrations (Fig. 8B).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Moreover, FAO rates and ATP levels were markedly upregulated by SLC31A1 overexpression in parental breast cancer cells (Fig. 8C and D).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel C",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Surprisingly, CCK8-analysis revealed that SLC31A1-facilitated proliferation of T47D and MCF7 cells was significantly abolished when CPT1A expression was inhibited by siCPT1A and ETO (Fig. 8E), which was validated by EdU staining (Fig. 8F and G), evidenced by the strongly decreased EdU-positive cells.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel E",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel F",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel E",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel E",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Transwell analysis further demonstrated that CPT1A expression suppression abolished the promotive effect of SLC31A1 on the invasion of breast cancer cells (Fig. 8H and I).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel H",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "In addition, in T47D and MCF7 cells overexpressing SLC31A1, CPT1A inhibition significantly reduced the FAO rates and ATP levels (Fig. 8J and K), along with diminished expression levels of CPT1A (Fig. 8L).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel J",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel L",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel L",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel L",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "As shown in Fig. 9A-C, TAM treatment had no significant effect on tumor growth compared to the control group; however, stable SLC31A1 knockdown not only significantly reduced the tumor growth rates and tumor weight, but also enhanced the response of these mice to TAM treatment, as indicated by the much lower tumor volume and weight.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "H&E staining indicated that the tumor cell density was significantly reduced in mice receiving TAM and shSLC31A1 combinatorial treatments (Fig. 9D).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "IHC staining further demonstrated that SLC31A1 deletion markedly decreased the positive expression of KI-67, CPT1A, and N-Cadherin in tumor sections, and enhanced the inhibitory effect of TAM on these molecules in mice bearing MCF7/TR tumors (Fig. 9D and E).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Furthermore, IF staining identified that SLC31A1 depletion induced higher Caspase-3 cleavage levels in tumor tissues, which were further enhanced in these mice receiving TAM plus shSLC31A1 (Fig. 9F).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Among these DEGs, SLC31A1, a copper transporter, was highly expressed in the recurrent tumor specimens (Fig. 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Meanwhile, a gradually increasing SLC31A1 was detected in advanced-stage tumor specimens compared to those in the early stage (Fig. 1B and C).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "To further explore the prognostic value and expression of SLC31A1, the TCGA database was analyzed, and the result demonstrated that SLC31A1 expression was significantly upregulated in breast invasive carcinoma (BRCA) samples compared to the paired normal samples (Fig. 1D).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Additionally, higher SLC31A1 expression levels predicted poorer overall survival and progress-free interval survival rates than patients with lower SLC31A1 expression levels (Fig. 1E and F).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel E",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The results in Fig. 1G showed that SLC31A1 expression was significantly up-regulated in breast tumor tissues with ≥25-75% stained cells, while its corresponding normal tissues were moderately stained or unstained.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel G",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Among these DEGs, SLC31A1, a copper transporter, was highly expressed in the recurrent tumor specimens (Fig. 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Meanwhile, a gradually increasing SLC31A1 was detected in advanced-stage tumor specimens compared to those in the early stage (Fig. 1B and C).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "To further explore the prognostic value and expression of SLC31A1, the TCGA database was analyzed, and the result demonstrated that SLC31A1 expression was significantly upregulated in breast invasive carcinoma (BRCA) samples compared to the paired normal samples (Fig. 1D).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Additionally, higher SLC31A1 expression levels predicted poorer overall survival and progress-free interval survival rates than patients with lower SLC31A1 expression levels (Fig. 1E and F).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel E",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The results in Fig. 1G showed that SLC31A1 expression was significantly up-regulated in breast tumor tissues with ≥25-75% stained cells, while its corresponding normal tissues were moderately stained or unstained.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel G",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "SLC31A1 expression levels are up-regulated in ER-positive breast cancer patients\nIn this part, we verified higher expression of SLC31A1 in BRCA tissues compared to normal tissues through TIMER analysis (Fig. 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Despite detecting a positive correlation between SLC31A1 and ERBB2 (HER2) in BRCA samples, there was no significant difference observed between SLC31A1 and HER2 in BRCA-Basal and -Her2 specimens (Fig. 2B-E).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Additionally, no significant difference was detected between SLC31A1 expression and PGR expression in BRCA-Basal and BRCA samples (Fig. 2B and C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In vitro studies further demonstrated that SLCA31A mRNA and protein expression levels were higher in ER-positive breast cancer cell lines (T47D, MCF7, BT474, ZR-75-1), while being undetectable or slightly expressed in ER-negative breast cancer cell lines (MB231, HCC1954, MB453) and the normal epithelial cell line (MCF10A) (Fig. 2F-H).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In this part, we verified higher expression of SLC31A1 in BRCA tissues compared to normal tissues through TIMER analysis (Fig. 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Despite detecting a positive correlation between SLC31A1 and ERBB2 (HER2) in BRCA samples, there was no significant difference observed between SLC31A1 and HER2 in BRCA-Basal and -Her2 specimens (Fig. 2B-E).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Additionally, no significant difference was detected between SLC31A1 expression and PGR expression in BRCA-Basal and BRCA samples (Fig. 2B and C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In vitro studies further demonstrated that SLCA31A mRNA and protein expression levels were higher in ER-positive breast cancer cell lines (T47D, MCF7, BT474, ZR-75-1), while being undetectable or slightly expressed in ER-negative breast cancer cell lines (MB231, HCC1954, MB453) and the normal epithelial cell line (MCF10A) (Fig. 2F-H).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "RT-qPCR results demonstrated that SLC31A1 was highly expressed in ER-positive breast cancer specimens in comparison to the matched adjacent normal tissues (Fig. 3A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Notably, much stronger SLC31A1 gene expression levels were detected in ER-positive breast cancer samples from patients with recurrence (R) than those of the patients without recurrence (NR) (Fig. 3C).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The IHC results revealed significantly stronger SLC31A1 protein expression levels in tumor sections collected from ER-positive breast cancer tissues with recurrence compared to the non-recurrent samples (Fig. 3D).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The IF staining analysis indicated that post-treatment tumors from the NR group exhibited similar SLC31A1 expression levels to their pre-treatment counterparts (Fig. 3E and F).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel E",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, post-treatment tumors from non-responders with recurrence showed a marked increase in SLC31A1 expression levels compared to their pre-treatment counterparts (Fig. 3G and H).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel G",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "IF staining results indicated that SLC31A1 expression was highly elevated in metastatic tissues compared to the primary tumor tissues (Fig. 3I and J).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel I",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "RT-qPCR results demonstrated that SLC31A1 was highly expressed in ER-positive breast cancer specimens in comparison to the matched adjacent normal tissues (Fig. 3A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Notably, much stronger SLC31A1 gene expression levels were detected in ER-positive breast cancer samples from patients with recurrence (R) than those of the patients without recurrence (NR) (Fig. 3C).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The IHC results revealed significantly stronger SLC31A1 protein expression levels in tumor sections collected from ER-positive breast cancer tissues with recurrence compared to the non-recurrent samples (Fig. 3D).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The IF staining analysis indicated that post-treatment tumors from the NR group exhibited similar SLC31A1 expression levels to their pre-treatment counterparts (Fig. 3E and F).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel E",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, post-treatment tumors from non-responders with recurrence showed a marked increase in SLC31A1 expression levels compared to their pre-treatment counterparts (Fig. 3G and H).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel G",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "IF staining results indicated that SLC31A1 expression was highly elevated in metastatic tissues compared to the primary tumor tissues (Fig. 3I and J).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel I",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "SLC31A1 deficiency rescues chemosensitivity in ER-positive breast cancer cells\nSubsequently, in vitro experiments were carried out to further investigate the impact of SLC31A1 expression changes on breast cancer progression and the underlying mechanisms using the TAM-sensitive breast cancer cell lines T47D and MCF7, and the constructed TAM-resistant (TR) ER-positive breast cancer cell lines (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Initially, RT-qPCR results indicated that T47D/TR and MCF7/TR cells exhibited significantly elevated expression of SLC31A1 at the mRNA level compared to the corresponding sensitive groups (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Western blot and IF staining confirmed significantly stronger SLC31A1 protein expression levels in T47D/TR and MCF7/TR cells than in the chemosensitive cell lines (Fig. 4C and D, Supplementary Fig. 1A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "RT-qPCR and western blot results confirmed the successful knockdown of SLC31A1 in breast cancer cells (Fig. 4E and F).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "More importantly, shSLC31A1 significantly enhanced the sensitivity of T47D/TR and MCF7/TR cells to TAM treatment, as indicated by the decreased cell viability through CCK-8 analysis (Fig. 4G).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Similarly, EdU staining confirmed that SLC31A1 depletion significantly reduced the proliferative capacity of T47D/TR and MCF7/TR cells in response to TAM incubation, which was comparable to the TAM single-treatment group (Fig. 4H).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel H",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel H",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel H",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Transwell analysis demonstrated that TAM had no significant effect on the invasion of T47D/TR and MCF7/TR cells, while shSLC31A1 infection strongly inhibited the invasive ability of TAM-resistant breast cancer cells (Fig. 4I), accompanied by a marked decrease in the expression of invasive markers, including N-Cadherin, VEFG, and matrix metalloproteinase-9 (MMP9) (Supplementary Fig. 2A-C).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel I",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel I",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel I",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Subsequently, in vitro experiments were carried out to further investigate the impact of SLC31A1 expression changes on breast cancer progression and the underlying mechanisms using the TAM-sensitive breast cancer cell lines T47D and MCF7, and the constructed TAM-resistant (TR) ER-positive breast cancer cell lines (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Initially, RT-qPCR results indicated that T47D/TR and MCF7/TR cells exhibited significantly elevated expression of SLC31A1 at the mRNA level compared to the corresponding sensitive groups (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Western blot and IF staining confirmed significantly stronger SLC31A1 protein expression levels in T47D/TR and MCF7/TR cells than in the chemosensitive cell lines (Fig. 4C and D, Supplementary Fig. 1A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "RT-qPCR and western blot results confirmed the successful knockdown of SLC31A1 in breast cancer cells (Fig. 4E and F).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "More importantly, shSLC31A1 significantly enhanced the sensitivity of T47D/TR and MCF7/TR cells to TAM treatment, as indicated by the decreased cell viability through CCK-8 analysis (Fig. 4G).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Similarly, EdU staining confirmed that SLC31A1 depletion significantly reduced the proliferative capacity of T47D/TR and MCF7/TR cells in response to TAM incubation, which was comparable to the TAM single-treatment group (Fig. 4H).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel H",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel H",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel H",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Transwell analysis demonstrated that TAM had no significant effect on the invasion of T47D/TR and MCF7/TR cells, while shSLC31A1 infection strongly inhibited the invasive ability of TAM-resistant breast cancer cells (Fig. 4I), accompanied by a marked decrease in the expression of invasive markers, including N-Cadherin, VEFG, and matrix metalloproteinase-9 (MMP9) (Supplementary Fig. 2A-C).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel I",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel I",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel I",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "SLC31A1 promotes the proliferation and invasion of ER-positive breast cancer cells in vitro\nTo further confirm the association between SLC31A1 and TAM resistance in ER-positive breast cancer cells, we overexpressed SLC31A1 in parental T47D and MCF7 cells, which were identified by RT-qPCR and western blot assays (Fig. 5A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As anticipated, CCK-8 analysis indicated that SLC31A1 overexpression significantly restored the proliferation of T47D and MCF7 cells compared with the oe-Vec control group (Fig. 5C).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Notably, the TAM-restricted proliferation of T47D and MCF7 cells was notably abolished upon SLC31A1 overexpression (Fig. 5D).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Similarly, oe-SLC31A1 not only strongly promoted the invasion of T47D and MCF7 cells but also rescued the invasive ability of breast cancer cells (Fig. 5E), as evidenced by the increased number of invaded cells.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Consistent with this, the suppressed expression levels of N-Cadherin, VEGF, and MMP9 in T47D and MCF7 cells by TAM were significantly reduced when SLC31A1 was overexpressed (Fig. 5F).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "To further confirm the association between SLC31A1 and TAM resistance in ER-positive breast cancer cells, we overexpressed SLC31A1 in parental T47D and MCF7 cells, which were identified by RT-qPCR and western blot assays (Fig. 5A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As anticipated, CCK-8 analysis indicated that SLC31A1 overexpression significantly restored the proliferation of T47D and MCF7 cells compared with the oe-Vec control group (Fig. 5C).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Notably, the TAM-restricted proliferation of T47D and MCF7 cells was notably abolished upon SLC31A1 overexpression (Fig. 5D).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Similarly, oe-SLC31A1 not only strongly promoted the invasion of T47D and MCF7 cells but also rescued the invasive ability of breast cancer cells (Fig. 5E), as evidenced by the increased number of invaded cells.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Consistent with this, the suppressed expression levels of N-Cadherin, VEGF, and MMP9 in T47D and MCF7 cells by TAM were significantly reduced when SLC31A1 was overexpressed (Fig. 5F).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As shown in Fig. 6A, we found higher copper concentrations in T47D/TR and MCF7/TR cells than that of their parental cell lines.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "We discovered that 481 genes were downregulated in T47D/TR cells relative to the control ones, encompassing CPT1A (Fig. 6B), a crucial gene in mediating the FAO process [29].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Further functional enrichment analysis of these DEGs by KEGG indicated that these signals were primarily implicated in the PPAR signaling pathway, fatty acid metabolism, gap junction, endocrine resistance, and fatty acid degradation (Fig. 6C).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "GSEA based on the acquired DEGs consistently disclosed that SLC31A1 was affiliated with fatty acid β-oxidation and metabolism (Fig. 6D).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "RT-qPCR results further demonstrated that the deletion of SLC31A1 conspicuously alleviated the expression of genes specifically implicated in FAO, including CPT1A, CPT1B, ACOX1, and 3-hydroxymethylglutaryl-CoA synthase 2 (HMGCS2), but augmented the fatty acid synthesis-related genes fatty acid synthase (FASN), acetyl-CoA carboxylase (ACC), and stearoyl-CoA desaturase (SCD) (Fig. 6E).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel E",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel E",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel E",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "RT-qPCR and western blot assays indicated that T47D/TR and MCF7/TR cells manifested stronger CPT1A mRNA and protein expression levels than those of the parental breast cancer cell lines (Fig. 6F and G).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel F",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "As anticipated, higher FAO and ATP levels were detected in T47D/TR and MCF7/TR compared to the chemosensitive breast cancer cell lines (Fig. 6H and I).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel H",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Notably, CPT1A deficiency significantly enhanced the chemosensitivity of T47D/TR and MCF7/TR cells to TAM incubation by CCK-8 analysis (Fig. 6J).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel J",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel J",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel J",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "In accordance with expectation, CPT1A deletion resulted in significantly higher lipid deposition in TAM-resistant T47D and MCF7 cells (Fig. 6K), as indicated by the larger size of lipid droplets, revealing the limited FAO process.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel K",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel K",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel K",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Furthermore, PO-induced mitochondrial injury was exacerbated in T47D/TR and MCF7/TR cells transfected with siCPT1A (Fig. 6L).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel L",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel L",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel L",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "As shown in Fig. 6A, we found higher copper concentrations in T47D/TR and MCF7/TR cells than that of their parental cell lines.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "We discovered that 481 genes were downregulated in T47D/TR cells relative to the control ones, encompassing CPT1A (Fig. 6B), a crucial gene in mediating the FAO process [29].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Further functional enrichment analysis of these DEGs by KEGG indicated that these signals were primarily implicated in the PPAR signaling pathway, fatty acid metabolism, gap junction, endocrine resistance, and fatty acid degradation (Fig. 6C).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "GSEA based on the acquired DEGs consistently disclosed that SLC31A1 was affiliated with fatty acid β-oxidation and metabolism (Fig. 6D).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "RT-qPCR results further demonstrated that the deletion of SLC31A1 conspicuously alleviated the expression of genes specifically implicated in FAO, including CPT1A, CPT1B, ACOX1, and 3-hydroxymethylglutaryl-CoA synthase 2 (HMGCS2), but augmented the fatty acid synthesis-related genes fatty acid synthase (FASN), acetyl-CoA carboxylase (ACC), and stearoyl-CoA desaturase (SCD) (Fig. 6E).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel E",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel E",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel E",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "RT-qPCR and western blot assays indicated that T47D/TR and MCF7/TR cells manifested stronger CPT1A mRNA and protein expression levels than those of the parental breast cancer cell lines (Fig. 6F and G).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel F",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "As anticipated, higher FAO and ATP levels were detected in T47D/TR and MCF7/TR compared to the chemosensitive breast cancer cell lines (Fig. 6H and I).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel H",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Notably, CPT1A deficiency significantly enhanced the chemosensitivity of T47D/TR and MCF7/TR cells to TAM incubation by CCK-8 analysis (Fig. 6J).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel J",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel J",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel J",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "In accordance with expectation, CPT1A deletion resulted in significantly higher lipid deposition in TAM-resistant T47D and MCF7 cells (Fig. 6K), as indicated by the larger size of lipid droplets, revealing the limited FAO process.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel K",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel K",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel K",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Furthermore, PO-induced mitochondrial injury was exacerbated in T47D/TR and MCF7/TR cells transfected with siCPT1A (Fig. 6L).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel L",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel L",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel L",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Copper/SLC31A1 enhances CPT1A expression levels in chemoresistant breast cancer cells\nTo explore the physiological effects of copper on CPT1A expression in TAM-resistant breast cancer cells, we discovered that copper supplementation led to CPT1A expression levels in a dose-dependent manner, and importantly, SLC31A1 deletion could significantly abrogate copper-triggered increase of CPT1A in T47D/TR and MCF7/TR cell lines (Fig. 7A).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Moreover, CPT1A suppression by its specific inhibitor ETO or siCPT1A markedly mitigated CPT1A expression levels in T47D/TR and MCF7/TR cells under copper exposure (Fig. 7B).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Subsequently, we found that copper-induced CPT1A up-regulation was potently antagonized by copper chelator TTM in chemoresistant breast cancer cell lines (Fig. 7C).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "To explore the physiological effects of copper on CPT1A expression in TAM-resistant breast cancer cells, we discovered that copper supplementation led to CPT1A expression levels in a dose-dependent manner, and importantly, SLC31A1 deletion could significantly abrogate copper-triggered increase of CPT1A in T47D/TR and MCF7/TR cell lines (Fig. 7A).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Moreover, CPT1A suppression by its specific inhibitor ETO or siCPT1A markedly mitigated CPT1A expression levels in T47D/TR and MCF7/TR cells under copper exposure (Fig. 7B).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Subsequently, we found that copper-induced CPT1A up-regulation was potently antagonized by copper chelator TTM in chemoresistant breast cancer cell lines (Fig. 7C).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "As expected, promoting SLC31A1 expression significantly enhanced CPT1A in T47D and MCF7 cells (Fig. 8A), along with higher copper concentrations (Fig. 8B).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Moreover, FAO rates and ATP levels were markedly upregulated by SLC31A1 overexpression in parental breast cancer cells (Fig. 8C and D).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel C",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Surprisingly, CCK8-analysis revealed that SLC31A1-facilitated proliferation of T47D and MCF7 cells was significantly abolished when CPT1A expression was inhibited by siCPT1A and ETO (Fig. 8E), which was validated by EdU staining (Fig. 8F and G), evidenced by the strongly decreased EdU-positive cells.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel E",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel F",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel E",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel E",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Transwell analysis further demonstrated that CPT1A expression suppression abolished the promotive effect of SLC31A1 on the invasion of breast cancer cells (Fig. 8H and I).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel H",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "In addition, in T47D and MCF7 cells overexpressing SLC31A1, CPT1A inhibition significantly reduced the FAO rates and ATP levels (Fig. 8J and K), along with diminished expression levels of CPT1A (Fig. 8L).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel J",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel L",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel L",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel L",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "As expected, promoting SLC31A1 expression significantly enhanced CPT1A in T47D and MCF7 cells (Fig. 8A), along with higher copper concentrations (Fig. 8B).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Moreover, FAO rates and ATP levels were markedly upregulated by SLC31A1 overexpression in parental breast cancer cells (Fig. 8C and D).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel C",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Surprisingly, CCK8-analysis revealed that SLC31A1-facilitated proliferation of T47D and MCF7 cells was significantly abolished when CPT1A expression was inhibited by siCPT1A and ETO (Fig. 8E), which was validated by EdU staining (Fig. 8F and G), evidenced by the strongly decreased EdU-positive cells.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel E",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel F",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel E",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel E",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Transwell analysis further demonstrated that CPT1A expression suppression abolished the promotive effect of SLC31A1 on the invasion of breast cancer cells (Fig. 8H and I).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel H",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "In addition, in T47D and MCF7 cells overexpressing SLC31A1, CPT1A inhibition significantly reduced the FAO rates and ATP levels (Fig. 8J and K), along with diminished expression levels of CPT1A (Fig. 8L).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel J",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel L",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel L",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel L",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "As shown in Fig. 9A-C, TAM treatment had no significant effect on tumor growth compared to the control group; however, stable SLC31A1 knockdown not only significantly reduced the tumor growth rates and tumor weight, but also enhanced the response of these mice to TAM treatment, as indicated by the much lower tumor volume and weight.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "H&E staining indicated that the tumor cell density was significantly reduced in mice receiving TAM and shSLC31A1 combinatorial treatments (Fig. 9D).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "IHC staining further demonstrated that SLC31A1 deletion markedly decreased the positive expression of KI-67, CPT1A, and N-Cadherin in tumor sections, and enhanced the inhibitory effect of TAM on these molecules in mice bearing MCF7/TR tumors (Fig. 9D and E).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Furthermore, IF staining identified that SLC31A1 depletion induced higher Caspase-3 cleavage levels in tumor tissues, which were further enhanced in these mice receiving TAM plus shSLC31A1 (Fig. 9F).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "As shown in Fig. 9A-C, TAM treatment had no significant effect on tumor growth compared to the control group; however, stable SLC31A1 knockdown not only significantly reduced the tumor growth rates and tumor weight, but also enhanced the response of these mice to TAM treatment, as indicated by the much lower tumor volume and weight.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "H&E staining indicated that the tumor cell density was significantly reduced in mice receiving TAM and shSLC31A1 combinatorial treatments (Fig. 9D).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "IHC staining further demonstrated that SLC31A1 deletion markedly decreased the positive expression of KI-67, CPT1A, and N-Cadherin in tumor sections, and enhanced the inhibitory effect of TAM on these molecules in mice bearing MCF7/TR tumors (Fig. 9D and E).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Furthermore, IF staining identified that SLC31A1 depletion induced higher Caspase-3 cleavage levels in tumor tissues, which were further enhanced in these mice receiving TAM plus shSLC31A1 (Fig. 9F).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Taken together, we concluded that SLC31A1 upregulation enhanced copper transportation into breast cancer cells, which drove CPT1A expression, followed by FAO elevation, thereby facilitating the proliferation, EMT process, and TAM resistance, and suppressing apoptosis in ER-positive breast cancer cells (Fig. 9G).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "In summary, our findings uncovered that SLC31A1/copper axis was a significant drug-resistant factor, which could promote the proliferation, EMT and chemoresistance but restrain apoptosis in ER-positive breast cancer through promoting the expression of CPT1A and associated FAO process (Fig. 9G).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Taken together, we concluded that SLC31A1 upregulation enhanced copper transportation into breast cancer cells, which drove CPT1A expression, followed by FAO elevation, thereby facilitating the proliferation, EMT process, and TAM resistance, and suppressing apoptosis in ER-positive breast cancer cells (Fig. 9G).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "In summary, our findings uncovered that SLC31A1/copper axis was a significant drug-resistant factor, which could promote the proliferation, EMT and chemoresistance but restrain apoptosis in ER-positive breast cancer through promoting the expression of CPT1A and associated FAO process (Fig. 9G).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      }
    ]
  }
]